<!DOCTYPE html>
<html lang="en"><head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge"><!-- Begin Jekyll SEO tag v2.8.0 -->
<title>Kidney and Adrenal Malignacies | Pediatric Urology Book</title>
<meta name="generator" content="Jekyll v4.2.2" />
<meta property="og:title" content="Kidney and Adrenal Malignacies" />
<meta name="author" content="Arlen AM, Gundeti MS, López P-J, Rove KO" />
<meta property="og:locale" content="en" />
<meta name="description" content="By Jonathan P. Walker,1 Nicholas G. Cost,2 &amp; Amanda F. Saltzman3 1 University of Tennessee Chattanooga, Department of Urology, Chattanooga, TN, USA 3 University of Colorado, Department of Surgery, Division of Urology, &amp; Children’s Hospital Colorado, Aurora, CO, USA 3 University of Kentucky, Department or Urology &amp; Pediatrics, Lexington, KY, USA" />
<meta property="og:description" content="By Jonathan P. Walker,1 Nicholas G. Cost,2 &amp; Amanda F. Saltzman3 1 University of Tennessee Chattanooga, Department of Urology, Chattanooga, TN, USA 3 University of Colorado, Department of Surgery, Division of Urology, &amp; Children’s Hospital Colorado, Aurora, CO, USA 3 University of Kentucky, Department or Urology &amp; Pediatrics, Lexington, KY, USA" />
<link rel="canonical" href="https://beta.pediatricurologybook.com/es/book/chapters/08-42_kidney-and-adrenal-malignacies/" />
<meta property="og:url" content="https://beta.pediatricurologybook.com/book/chapters/08-42_kidney-and-adrenal-malignacies/" />
<meta property="og:site_name" content="Pediatric Urology Book" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2023-01-29T15:52:48-07:00" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="Kidney and Adrenal Malignacies" />
<script type="application/ld+json">
{"@context":"https://schema.org","@type":"BlogPosting","author":{"@type":"Person","name":"Arlen AM, Gundeti MS, López P-J, Rove KO"},"dateModified":"2023-01-29T15:12:55-07:00","datePublished":"2023-01-29T15:52:48-07:00","description":"By Jonathan P. Walker,1 Nicholas G. Cost,2 &amp; Amanda F. Saltzman3 1 University of Tennessee Chattanooga, Department of Urology, Chattanooga, TN, USA 3 University of Colorado, Department of Surgery, Division of Urology, &amp; Children’s Hospital Colorado, Aurora, CO, USA 3 University of Kentucky, Department or Urology &amp; Pediatrics, Lexington, KY, USA","headline":"Kidney and Adrenal Malignacies","mainEntityOfPage":{"@type":"WebPage","@id":"https://beta.pediatricurologybook.com/book/chapters/08-42_kidney-and-adrenal-malignacies/"},"url":"https://beta.pediatricurologybook.com/book/chapters/08-42_kidney-and-adrenal-malignacies/"}</script>
<!-- End Jekyll SEO tag -->
<meta http-equiv="Content-Language" content="es">
<link rel="alternate" hreflang="en" href="https://beta.pediatricurologybook.com/book/chapters/08-42_kidney-and-adrenal-malignacies/"/>
<link rel="alternate" hreflang="es" href="https://beta.pediatricurologybook.com/es/book/chapters/08-42_kidney-and-adrenal-malignacies/"/>
<link rel="alternate" hreflang="zh" href="https://beta.pediatricurologybook.com/zh/book/chapters/08-42_kidney-and-adrenal-malignacies/"/>
<link rel="alternate" hreflang="pt" href="https://beta.pediatricurologybook.com/pt/book/chapters/08-42_kidney-and-adrenal-malignacies/"/>

  <!-- Favicon -->
  <link rel="icon" href="https://beta.pediatricurologybook.com/es/favicon.ico" type="image/x-icon" > <!-- 32×32 -->
  <link rel="icon" href="https://beta.pediatricurologybook.com/assets/site-img/favicons/icon.svg" type="image/svg+xml">    <!-- res independent -->
  <link rel="apple-touch-icon" href="https://beta.pediatricurologybook.com/assets/site-img/favicons/apple-touch-icon.png"> <!-- 180×180 -->
  <link rel="manifest" href="/es/manifest.webmanifest">
  
  <!-- Mobile Metas -->
  <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1.0, shrink-to-fit=no">

  <!-- Analytics --><!-- Vendor CSS -->
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/bootstrap/css/bootstrap.min.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/fontawesome-free/css/all.min.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/animate/animate.min.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/rs-plugin/css/navigation.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/owl.carousel/assets/owl.carousel.min.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/vendor/owl.carousel/assets/owl.theme.default.min.css">
  
  <!-- Theme CSS -->
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/css/theme.css">
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/css/theme-elements.css">

  <!-- Skin CSS -->
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/css/skins/skin-pub.css"> 
  
  <!-- Theme Custom CSS -->
  <link rel="stylesheet" href="https://beta.pediatricurologybook.com/assets/css/custom.css">
  
  <!-- JS Libraries -->
  <script src="https://beta.pediatricurologybook.com/assets/vendor/modernizr/modernizr.min.js"></script>
</head>
<body data-plugin-page-transition>

    <div class="body" aria-label="Content">    
    
    <header id="header" data-plugin-options="{'stickyEnabled': true, 'stickyEnableOnBoxed': true, 'stickyEnableOnMobile': true, 'stickyStartAt': 108, 'stickySetTop': '-109px', 'stickyChangeLogo': true}">
      <div class="header-body">
        <div class="header-container container">
          <div class="header-row">
            <div class="header-column">
              <div class="header-row">
                <div class="header-logo">
                  <a class="site-title" rel="author" href="https://beta.pediatricurologybook.com/es/">
                    <img width="254" height="165" data-sticky-width="126" data-sticky-height="80" data-sticky-top="95" alt="Pedatric Urology Book" src="https://beta.pediatricurologybook.com/assets/site-img/pediatricurologybook-new.svg">
                  </a>
                </div>
              </div>
            </div>
            <div class="header-column justify-content-end">
              <div class="header-row pt-3 mb-3">
                <nav class="header-nav-top">
                  <ul class="nav nav-pills">
                    <li class="nav-item nav-item-anim-icon d-none d-md-block">
                      <a class="nav-link pl-0" href="https://beta.pediatricurologybook.com/es/about-us/"><i class="fa fa-angle-right pr-1"></i>Sobre Nosotros</a>
                    </li>
                    <li class="nav-item nav-item-anim-icon d-none d-md-block">
                      <a class="nav-link" href="https://beta.pediatricurologybook.com/es/contact-us/"><i class="fa fa-angle-right pr-1"></i>Contacta con Nosotros</a>
                    </li>
                    <li class="nav-item dropdown nav-item-left-border d-block nav-item-left-border-remove nav-item-left-border-md-show">
                      
                      <a class="nav-link" href="#" role="button" id="dropdown-language" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        <i class="fas fa-globe-americas"></i> Español
                        <i class="fas fa-angle-down"></i>
                      </a>
                      <div class="dropdown-menu" aria-labelledby="dropdown-language">
                        
                          
                          
                          
                          
                          <a class="dropdown-item" href="https://beta.pediatricurologybook.com/book/chapters/08-42_kidney-and-adrenal-malignacies/">English</a>
                          
                        
                          
                            
                          
                          
                          
                          
                          <a class="dropdown-item" href="https://beta.pediatricurologybook.com/zh/book/chapters/08-42_kidney-and-adrenal-malignacies/">简体中文</a>
                          
                        
                          
                          
                          
                          
                          <a class="dropdown-item" href="https://beta.pediatricurologybook.com/pt/book/chapters/08-42_kidney-and-adrenal-malignacies/">Português</a>
                          
                        
                      </div>
                    </li>
                  </ul>
                </nav>
                <div class="header-nav-features header-nav-features-no-border header-nav-features-md-show-border d-none d-md-inline-flex">
                    <div class="simple-search input-group w-auto">
                      <input class="form-control text-1" id="search-input" name="q" type="text" value="" placeholder="Buscar...">
                      <span class="input-group-btn">
                        <button class="btn" type="submit">
                          <i class="fa fa-search"></i>
                        </button>
                      </span>
                      <ul id="search-results">
                      </ul>
                    </div>
                </div>
              </div>
              <div class="header-row">
                <div class="header-nav pt-1">
                  <div class="header-nav-main header-nav-main-effect-1 header-nav-main-sub-effect-1">
                    <nav class="collapse">
                      <ul class="nav nav-pills" id="mainNav">
                        <li><a href="https://beta.pediatricurologybook.com/es/"><i class="fas fa-home pr-1"></i>Inicio</a></li>
                        <li><a href="https://beta.pediatricurologybook.com/es/book/"><i class="fas fa-book pr-1"></i>Leer el Libro</a></li>
                        <li><a href="https://beta.pediatricurologybook.com/es/editors/"><i class="fas fa-pen-fancy pr-1"></i>Editores</a></li>
                        <li><a href="https://beta.pediatricurologybook.com/es/contributors/"><i class="fas fa-code-branch pr-1"></i>Autores</a></li>
                        <li><a href="https://beta.pediatricurologybook.com/es/sponsors/"><i class="fas fa-user-md pr-1"></i>Patrocinadores</a></li>
                      </ul>
                    </nav>
                  </div> <!-- end header-nav-main -->
                  <button class="btn header-btn-collapse-nav" data-toggle="collapse" data-target=".header-nav-main nav">
                      <i class="fas fa-bars"></i>
                  </button>
                </div> <!-- end header-nav -->
              </div> <!-- end header-row -->
            </div> <!-- end header-column -->
          </div> <!-- end header-row -->
        </div> <!-- end header-container -->
      </div> <!-- end header-body -->
    </header>
        
    
    <div role="main" class="main">
      <section class="page-header page-header-modern bg-color-primary page-header-md">
        <div class="container">
          <div class="row">
            <div class="col-md-8 order-2 order-md-1 align-self-center p-static">
              <h1>42: Kidney and Adrenal Malignacies</h1>
            </div>
            
            <div class="col-md-4 order-1 order-md-2 align-self-center">
              <ul class="breadcrumb d-block text-md-right breadcrumb-light">
              
                <li><a href="https://beta.pediatricurologybook.com/es/">Home</a></li>
              
                <li><a href="https://beta.pediatricurologybook.com/es/book/">Book</a></li>
              
                <li class="active"><a href="https://beta.pediatricurologybook.com/es/book/#section-08"> 08</a></li>
              </ul>
            </div>
          </div>
        </div>
      </section>
      <div class="container chapter chapter-08-42">
        <div class="row">
          <div class="col-lg-3 order-2 order-lg-1 mt-4 mt-lg-0 chapter-toc">
            <aside class="sidebar">
              <h5 class="font-weight-bold no_toc">Contenido del Capítulo</h5>
    
            <ul class="nav nav-list flex-column mb-5">
<li class="nav-item toc-h2"><a href="#tumors-of-the-adrenal-gland-pheochromocytoma-and-paraganglioma">Tumors of the Adrenal Gland: Pheochromocytoma and Paraganglioma</a>
<ul>
<li class="nav-item toc-h3"><a href="#introduction">Introduction</a></li>
<li class="nav-item toc-h3"><a href="#embryology">Embryology</a></li>
<li class="nav-item toc-h3"><a href="#epidemiology">Epidemiology</a></li>
<li class="nav-item toc-h3"><a href="#pathogenesis">Pathogenesis</a></li>
<li class="nav-item toc-h3"><a href="#evaluation-and-diagnosis">Evaluation and Diagnosis</a></li>
<li class="nav-item toc-h3"><a href="#treatment-options-and-their-outcomes">Treatment Options and Their Outcomes</a></li>
<li class="nav-item toc-h3"><a href="#suggested-follow-up">Suggested Follow Up</a></li>
<li class="nav-item toc-h3"><a href="#conclusions">Conclusions</a></li>
<li class="nav-item toc-h3"><a href="#key-points">Key Points</a></li>
</ul>
</li>
<li class="nav-item toc-h2"><a href="#wilms-tumor">Wilms’ Tumor</a>
<ul>
<li class="nav-item toc-h3"><a href="#introduction-1">Introduction</a></li>
<li class="nav-item toc-h3"><a href="#embryology-1">Embryology</a></li>
<li class="nav-item toc-h3"><a href="#epidemiology-1">Epidemiology</a></li>
<li class="nav-item toc-h3"><a href="#pathogenesis-1">Pathogenesis</a></li>
<li class="nav-item toc-h3"><a href="#evaluation-and-diagnosis-1">Evaluation and Diagnosis</a></li>
<li class="nav-item toc-h3"><a href="#treatment-options-and-their-outcomes-1">Treatment Options and Their Outcomes</a></li>
<li class="nav-item toc-h3"><a href="#special-treatment-scenarios">Special Treatment Scenarios</a></li>
<li class="nav-item toc-h3"><a href="#complications">Complications</a></li>
<li class="nav-item toc-h3"><a href="#suggested-follow-up-1">Suggested Follow Up</a></li>
<li class="nav-item toc-h3"><a href="#key-points-1">Key Points</a></li>
<li class="nav-item toc-h3"><a href="#suggested-readings">Suggested Readings</a></li>
<li class="nav-item toc-h3"><a href="#recommended-videos">Recommended Videos</a></li>
</ul>
</li>
<li class="nav-item toc-h2"><a href="#pediatric-non-wilms-renal-tumors">Pediatric Non-Wilms’ Renal Tumors</a>
<ul>
<li class="nav-item toc-h3"><a href="#introduction-2">Introduction</a></li>
<li class="nav-item toc-h3"><a href="#embryology-2">Embryology</a></li>
<li class="nav-item toc-h3"><a href="#epidemiology-2">Epidemiology</a></li>
<li class="nav-item toc-h3"><a href="#pathogenesis-2">Pathogenesis</a></li>
<li class="nav-item toc-h3"><a href="#evaluation-and-diagnosis-2">Evaluation and Diagnosis</a></li>
<li class="nav-item toc-h3"><a href="#treatment-options-and-outcomes">Treatment Options and Outcomes</a></li>
<li class="nav-item toc-h3"><a href="#complications-1">Complications</a></li>
<li class="nav-item toc-h3"><a href="#conclusions-1">Conclusions</a></li>
<li class="nav-item toc-h3"><a href="#key-points-2">Key Points</a></li>
<li class="nav-item toc-h3"><a href="#suggested-readings-1">Suggested Readings</a></li>
</ul>
</li>
<li class="nav-item toc-h2"><a href="#references">References</a></li>
</ul>
            
            </aside>
          </div>
          <div class="col-lg-9 order-1 order-lg-2 chapter-body">
            <p class="time-to-read"><i class="fas fa-info pr-2"></i><em>Le tomará aproximadamente 25 minutos leer este capítulo.</em></p>
                
            <p class="attribution">By <strong class="author-names">Jonathan P. Walker</strong>,<sup>1</sup> <strong class="author-names">Nicholas G. Cost</strong>,<sup>2</sup> &amp; <strong class="author-names">Amanda F. Saltzman</strong><sup>3</sup><br>
<em class="author-title"><sup>1</sup> University of Tennessee Chattanooga, Department of Urology, Chattanooga, TN, USA</em><br>
<em class="author-title"><sup>3</sup> University of Colorado, Department of Surgery, Division of Urology, &amp; Children’s Hospital Colorado, Aurora, CO, USA</em><br>
<em class="author-title"><sup>3</sup> University of Kentucky, Department or Urology &amp; Pediatrics, Lexington, KY, USA</em></p>

<h2 id="tumors-of-the-adrenal-gland-pheochromocytoma-and-paraganglioma">
<a class="anchor" href="#tumors-of-the-adrenal-gland-pheochromocytoma-and-paraganglioma" aria-hidden="true"><span class="octicon octicon-link"></span></a>Tumors of the Adrenal Gland: Pheochromocytoma and Paraganglioma</h2>

<h3 id="introduction">
<a class="anchor" href="#introduction" aria-hidden="true"><span class="octicon octicon-link"></span></a>Introduction</h3>

<p class="drop-caps">Pheochromocytoma (<abbr title="pheochromocytoma">PCC</abbr>) is a catecholamine secreting tumor. There are limited data available concerning management of this rare tumor in children and adolescents. Management is usually extrapolated from a combination of the adult guidelines and case reports/series. In the pediatric population, surgery is the mainstay of treatment, but there are recent advances in new treatments and management of metastatic disease.<a class="citation" href="#asai2017a"><span style="vertical-align: super">1,2</span></a></p>

<h3 id="embryology">
<a class="anchor" href="#embryology" aria-hidden="true"><span class="octicon octicon-link"></span></a>Embryology</h3>

<p><abbr title="pheochromocytoma">PCC</abbr> arises from the adrenal medulla, specifically the chromaffin cells.<a class="citation" href="#board2019a"><span style="vertical-align: super">3</span></a> If <abbr title="pheochromocytoma">PCC</abbr> arises outside the adrenal gland, it is called a paraganglioma (<abbr title="paraganglioma">PG</abbr>).</p>

<h3 id="epidemiology">
<a class="anchor" href="#epidemiology" aria-hidden="true"><span class="octicon octicon-link"></span></a>Epidemiology</h3>

<p>Overall, <abbr title="pheochromocytoma">PCC</abbr> has an annual incidence of 3 in 1 million individuals. Of all <abbr title="pheochromocytoma">PCC</abbr> diagnoses, 20% occur in children.<a class="citation" href="#board2019a"><span style="vertical-align: super">3</span></a> Although patients can be diagnosed at any age, in children, the mean age is 11–13 years.<a class="citation" href="#bausch2014a"><span style="vertical-align: super">4,5</span></a> Patients classically present with symptoms attributable to catecholamine excess: hypertension, headache, palpations, tremor, excessive sweating and facial pallor.<a class="citation" href="#lenders2014a"><span style="vertical-align: super">6</span></a> These symptoms can be episodic, but in children, they are more likely to be sustained.<a class="citation" href="#lenders2014a"><span style="vertical-align: super">6</span></a> Up to 2% of children with hypertension may have catecholamine secreting tumors compared to this being a rare cause (&lt;1%) in adults.<a class="citation" href="#lenders2014a"><span style="vertical-align: super">6</span></a></p>

<h3 id="pathogenesis">
<a class="anchor" href="#pathogenesis" aria-hidden="true"><span class="octicon octicon-link"></span></a>Pathogenesis</h3>

<p>Discussion of <abbr title="pheochromocytoma">PCC</abbr> centers around genetic predisposition. Despite the classic “rule of 10s” for <abbr title="pheochromocytoma">PCC</abbr>, about 40% of pediatric <abbr title="pheochromocytomas">PCCs</abbr> have a hereditary disposition. (<a href="#table-1" class="table-link">Table 1</a>) describes the known genetic syndromes associated with <abbr title="pheochromocytoma">PCC</abbr>.<a class="citation" href="#board2019a"><span style="vertical-align: super">3,7</span></a> The genetic link is so strong that up to 70–80% of pediatric patients with <abbr title="pheochromocytoma">PCC</abbr> or <abbr title="paraganglioma">PG</abbr> have an associated germline mutation. These germline mutations may or may not be a genetic syndrome or hereditary in nature.<a class="citation" href="#bausch2014a"><span style="vertical-align: super">4,8,9</span></a> In one study of 49 patients age &lt;20y with <abbr title="pheochromocytoma">PCC</abbr> or <abbr title="paraganglioma">PG</abbr>, almost 80% had a germline mutation involving Succinate Dehydrogenase (<abbr title="succinate dehydrogenase">SDH</abbr>), von Hippel Lindau (<abbr title="Von Hippel Lindau">VHL</abbr>), or Neurofibromatosis Type 1 (NF1).<a class="citation" href="#king2011a"><span style="vertical-align: super">8</span></a> When tested for RET (rearranged during transfection), <abbr title="Von Hippel Lindau">VHL</abbr>, and <abbr title="succinate dehydrogenase">SDH</abbr> mutations, 70% of patients &lt;10y, 51% of patients 10–20y and 16% of patients &gt;20y had an identifiable germline mutation.<a class="citation" href="#neumann2002a"><span style="vertical-align: super">9</span></a> Considering this strong association, all children, adolescents and young adults with <abbr title="pheochromocytoma">PCC</abbr> or <abbr title="paraganglioma">PG</abbr> should undergo genetic testing.<a class="citation" href="#b2018a"><span style="vertical-align: super">10</span></a> Similarly, for patients with either a family history or known genetic disposition (ex. Multiple Endocrine Neoplasia type 2 (MEN2) and <abbr title="Von Hippel Lindau">VHL</abbr>) should undergo regular screening, usually biochemical testing annually beginning at age 5y.<a class="citation" href="#jain2019a"><span style="vertical-align: super">11</span></a></p>

<p>MEN2 is an autosomal dominant disorder caused by an activating mutation in the RET oncogene. There is a &gt;50% risk of developing <abbr title="pheochromocytoma">PCC</abbr>.<a class="citation" href="#board2019a"><span style="vertical-align: super">3,5</span></a> About 20% of patients with MEN2B develop <abbr title="pheochromocytoma">PCC</abbr>, and all were associated with the classic M918T RET mutation.<a class="citation" href="#makri2019a"><span style="vertical-align: super">12</span></a> The majority are diagnosed with screening and few experience clinical symptoms, illustrating the importance of screening for early diagnosis.</p>

<p>Approximately 10–20% of patients with <abbr title="Von Hippel Lindau">VHL</abbr> will develop <abbr title="pheochromocytoma">PCC</abbr> or <abbr title="paraganglioma">PG</abbr>.<a class="citation" href="#board2019a"><span style="vertical-align: super">3</span></a> Children with <abbr title="Von Hippel Lindau">VHL</abbr> may present with <abbr title="pheochromocytoma">PCC</abbr> as the event that triggers a <abbr title="Von Hippel Lindau">VHL</abbr> diagnosis. These presentations may be atypical, including weight loss,<a class="citation" href="#igaki2018a"><span style="vertical-align: super">13</span></a> metastatic disease without symptoms after screening started,<a class="citation" href="#colvin2018a"><span style="vertical-align: super">14</span></a> and bilateral <abbr title="pheochromocytoma">PCC</abbr>.<a class="citation" href="#a2018a"><span style="vertical-align: super">15</span></a></p>

<p>Although less common, patients with NF1 have an increased risk of developing <abbr title="pheochromocytoma">PCC</abbr>.<a class="citation" href="#gruber2017a"><span style="vertical-align: super">16</span></a> Usually this is diagnosed at an older age and rarely in children.<a class="citation" href="#jain2019a"><span style="vertical-align: super">11</span></a> As such, for patients with NF1 biochemical screening should begin at age 10y.<a class="citation" href="#gruber2017a"><span style="vertical-align: super">16</span></a></p>

<p>Germline mutations of <abbr title="succinate dehydrogenase">SDH</abbr> complex genes and their association with <abbr title="pheochromocytoma">PCC</abbr> is a more recent discovery. It seems that a <abbr title="succinate dehydrogenase-A">SDHA</abbr> or B mutation is associated with a higher prevalence of aggressive and metastatic disease.<a class="citation" href="#king2011a"><span style="vertical-align: super">8</span></a> As such, asymptomatic carriers are often identified through genetic testing of family members with related diseases.<a class="citation" href="#tufton2017a"><span style="vertical-align: super">17</span></a> <abbr title="pheochromocytoma">PCC</abbr> associated with <abbr title="succinate dehydrogenase">SDH</abbr> mutations are generally biochemically silent, which necessitates serial imaging. In general, abdominal <abbr title="magnetic resonance imaging">MRI</abbr> every 18 months and <abbr title="magnetic resonance imaging">MRI</abbr> of the neck, thorax, abdomen and pelvis every 3 years is recommended.<a class="citation" href="#tufton2017a"><span style="vertical-align: super">17</span></a></p>

<p>Recently, there have been cases suggesting some type of a relationship between <abbr title="pheochromocytoma">PCC</abbr>/<abbr title="paraganglioma">PG</abbr> and cyanotic congenital heart disease.<a class="citation" href="#zhao2018a"><span style="vertical-align: super">18</span></a> The theory is that there may be a link between hypoxia-induced cellular pathways and tumorigensis.<a class="citation" href="#wcislak2019a"><span style="vertical-align: super">19</span></a></p>

<p><strong id="table-1" class="table-number">Table 1</strong> Characteristics and screening recommendations of syndromes associated with <abbr title="pheochromocytoma">PCC</abbr> (Peard, Cost, Saltzman Curr Opin Urol 2019)</p>

<table>
  <thead>
    <tr>
      <th>Disease</th>
      <th>Genetic mutation</th>
      <th>Stigmata of Disease</th>
      <th>Rate of <abbr title="pheochromocytoma">PCC</abbr> or <abbr title="paraganglioma">PG</abbr>
</th>
      <th>Surveillance</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><abbr title="Von Hippel Lindau">VHL</abbr></td>
      <td>
<abbr title="Von Hippel Lindau">VHL</abbr>  tumor suppressor (Colvin)</td>
      <td>Central nervous system and retinal hemangiomas, renal cell carcinoma, <abbr title="pheochromocytoma">PCC</abbr>, pancreatic neuroendocrine tumors, cysts (Dias Pereira)</td>
      <td>10% (<abbr title="pulmonary chondromas">PDQ</abbr>)</td>
      <td>Plasma or urine metanephrines annually starting at age 5y (Jain)</td>
    </tr>
    <tr>
      <td>MEN2A</td>
      <td>RET oncogene activation (Bholah)</td>
      <td>Medullary thyroid carcinoma, <abbr title="pheochromocytoma">PCC</abbr>, primary hyperparathyroidism (Dias Pereira)</td>
      <td>68% (Dias Pereira)</td>
      <td>Plasma or urine metanephrines annually starting at age 5y (Jain)</td>
    </tr>
    <tr>
      <td>MEN2B</td>
      <td>RET oncogene activation (Makri)</td>
      <td>Medullary thyroid carcinoma, <abbr title="pheochromocytoma">PCC</abbr>, multiple neuromas, marfanoid habitus (Bholah)</td>
      <td>50% (Makri)</td>
      <td>Plasma or urine metanephrines annually starting at age 5y (Jain)</td>
    </tr>
    <tr>
      <td>
<abbr title="neurofibromatosis">NF</abbr>-1</td>
      <td>NF1 gene mutation (Gruber)</td>
      <td>Café au lait lesions, axillary/inguinal freckling, neurofibromas, Lisch nodules, osseous lesions, <abbr title="pheochromocytoma">PCC</abbr>, <abbr title="gastrointestinal stromal tumor">GIST</abbr>, melanoma, breast, lung, colorectal carcinomas (Dias pereira)</td>
      <td>8% (Dias Pereira)</td>
      <td>Plasma or urine metanephrines every 3 years starting at age 10y (Gruber)</td>
    </tr>
    <tr>
      <td><abbr title="succinate dehydrogenase">SDH</abbr></td>
      <td>
<abbr title="succinate dehydrogenase">SDH</abbr> respiratory complex tumor suppressor (Jha)</td>
      <td>
<abbr title="pheochromocytoma">PCC</abbr>, <abbr title="paraganglioma">PG</abbr>, renal cell carcinoma, <abbr title="gastrointestinal stromal tumor">GIST</abbr> (settas)</td>
      <td>Not yet defined (Chen)</td>
      <td>
<abbr title="succinate dehydrogenase-B">SDHB</abbr>: <abbr title="magnetic resonance imaging">MRI</abbr> abdomen q18mos, <abbr title="magnetic resonance imaging">MRI</abbr> neck, thorax, pelvis q3y (Tufton) /// <abbr title="succinate dehydrogenase-A">SDHA</abbr>, <abbr title="succinate dehydrogenase-C">SDHC</abbr>, <abbr title="succinate dehydrogenase-D">SDHD</abbr>: require less frequent screening (Tufton)</td>
    </tr>
    <tr>
      <td>Carney Triad</td>
      <td>N/A</td>
      <td>
<abbr title="paraganglioma">PG</abbr>, gastrointestinal stromal tumors, pulmonary chondromas (<abbr title="pulmonary chondromas">PDQ</abbr>)</td>
      <td>50% (<abbr title="pulmonary chondromas">PDQ</abbr>)</td>
      <td>No defined screening</td>
    </tr>
  </tbody>
</table>

<h3 id="evaluation-and-diagnosis">
<a class="anchor" href="#evaluation-and-diagnosis" aria-hidden="true"><span class="octicon octicon-link"></span></a>Evaluation and Diagnosis</h3>

<p>While the majority of <abbr title="pheochromocytomas">PCCs</abbr> are benign, the systemic effects of catecholamine excess can have significant morbidity and mortality.<a class="citation" href="#chen2010a"><span style="vertical-align: super">7</span></a> Classically described is the “rule of 10s” (<a href="#table-2" class="table-link">Table 2</a>) To distinguish benign from malignant <abbr title="pheochromocytoma">PCC</abbr>, metastases must be identified.</p>

<p><strong id="table-2" class="table-number">Table 2</strong> “Rule of 10s”</p>

<table>
  <thead>
    <tr>
      <th>10%</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Extra adrenal</td>
    </tr>
    <tr>
      <td>Bilateral or multiple</td>
    </tr>
    <tr>
      <td>Genetic predisposition (actually 25%)</td>
    </tr>
    <tr>
      <td>Pediatric</td>
    </tr>
    <tr>
      <td>Malignant/metastasize (up to 36%)</td>
    </tr>
    <tr>
      <td>Associated with <abbr title="multiple endocrine neoplasia">MEN</abbr> syndromes</td>
    </tr>
    <tr>
      <td>Present with stroke</td>
    </tr>
    <tr>
      <td>Calcified</td>
    </tr>
    <tr>
      <td>Present without hypertension</td>
    </tr>
    <tr>
      <td>Recur</td>
    </tr>
    <tr>
      <td>Found incidentally</td>
    </tr>
    <tr>
      <td>Discussed 10× more common than actually seen</td>
    </tr>
  </tbody>
</table>

<p>Suggested methods of diagnosis are extrapolated from adult studies, but there is an ongoing debate about preference considering the goal of minimizing radiation exposure in children.</p>

<p>Once an adrenal mass is discovered, laboratory testing to evaluate for catecholamine excess is necessary. Plasma-free metanephrines or 24-hour urine metanephrines are superior to measurement of plasma catecholamines (i.e., norepinephrine, epinephrine) or urine vanillylmandelic acid, since the latter substances are only episodically released, while the metanephrines are constantly present as degradation products.<a class="citation" href="#boyle2007a"><span style="vertical-align: super">20</span></a></p>

<p>Several common medications may cause a false positive result, including selective serotonin reuptake inhibitors, tricyclic amines, monoamine oxidase inhibitors, and sympathomimetics including amphetamines, decongestants, caffeine or nicotine.<a class="citation" href="#jain2019a"><span style="vertical-align: super">11</span></a> Prior to lab testing, these medications should be stopped. Additionally, patients should be fasting and supine for at least 30 minutes prior to lab draw.<a class="citation" href="#lenders2014a"><span style="vertical-align: super">6,21</span></a> Blood draws in the seated position can cause a 5–7 fold increase in the rate of false positive results.<a class="citation" href="#boot2017a"><span style="vertical-align: super">22</span></a></p>

<p>Pediatric-specific reference ranges are nebulous and false-positives are high. In general, a false positive should be considered if levels are &lt;3-4 times normal and testing should be repeated.</p>

<p>Patients with laboratory confirmed catecholamine excess need cross sectional imaging. This should be either <abbr title="computed tomography">CT</abbr> or <abbr title="magnetic resonance imaging">MRI</abbr> of the abdomen, with &gt;90% sensitivity for adrenal <abbr title="pheochromocytoma">PCC</abbr> detection.<a class="citation" href="#bholah2017a"><span style="vertical-align: super">5</span></a> On T2 <abbr title="magnetic resonance imaging">MRI</abbr>, <abbr title="pheochromocytoma">PCC</abbr> is very bright, called the lightbulb sign. For patients with a high suspicion for <abbr title="pheochromocytoma">PCC</abbr> but inconclusive biochemical testing, and to assess for metastasis, multifocal disease, or regional extension, functional imaging is indicated. This includes <sup>123</sup>I- or <sup>131</sup>I-metaiodobenzylguanidine (<abbr title="metaiodobenzylguanidine">MIBG</abbr>) scintigraphy and positron emission tomography (<abbr title="positron emission tomography">PET</abbr>).<a class="citation" href="#bholah2017a"><span style="vertical-align: super">5</span></a> Both <abbr title="positron emission tomography">PET</abbr> and <sup>123</sup>I-<abbr title="metaiodobenzylguanidine">MIBG</abbr> are sensitive tests for tumor localization but <abbr title="positron emission tomography">PET</abbr> is preferred for identifying metastatic disease.<a class="citation" href="#sait2017a"><span style="vertical-align: super">23</span></a> Head-to-head comparisons of various types of cross-sectional imaging with or without radiopharmaceuticals have shown the superiority of Ga-DOTA(0)-Tyr(3)-octreotate (Ga-<abbr title="Ga-DOTA(0)-Tyr(3)-octreotate">DOTATATE</abbr>) <abbr title="positron emission tomography">PET</abbr> scans for localizing metastatic <abbr title="pheochromocytoma">PCC</abbr> and other paragangliomas.</p>

<h3 id="treatment-options-and-their-outcomes">
<a class="anchor" href="#treatment-options-and-their-outcomes" aria-hidden="true"><span class="octicon octicon-link"></span></a>Treatment Options and Their Outcomes</h3>

<p>Surgical resection is the gold standard treatment for <abbr title="pheochromocytoma">PCC</abbr>.<a class="citation" href="#bholah2017a"><span style="vertical-align: super">5</span></a> The key to surgical management is the appropriate pre- and perioperative management to preventing sequelae from hypertensive crisis.</p>

<p>With tumor manipulation by the surgeon, catecholamines may be released in large quantities and cause hypertensive crisis with cardiac arrhythmias, myocardial ischemia, pulmonary edema, and stroke.<a class="citation" href="#jain2019a"><span style="vertical-align: super">11</span></a> Various preoperative regimens have been described, but again management of pediatric patients is largely extrapolated from the adult literature.<a class="citation" href="#fishbein2013a"><span style="vertical-align: super">24</span></a> In <abbr title="pheochromocytoma">PCC</abbr>, there is a high level of catecholamines. These cause vasoconstriction of the peripheral vasculature. As such, the patient is hypovolemic. To counteract this, the alpha receptors are blocked, which dilates the peripheral vasculature. To counteract this drop in blood pressure due to hypovolemia, high salt intake and hydration help to increase intravascular volume.<a class="citation" href="#bholah2017a"><span style="vertical-align: super">5</span></a> Options for alpha blockade include phenoxybenzamine, doxazosin, prazosin, or terazosin.<a class="citation" href="#lenders2014a"><span style="vertical-align: super">6</span></a> Alternative regimens include a tyrosine hydroxylase inhibitors or calcium channel blockers.<a class="citation" href="#lebuffe2005a"><span style="vertical-align: super">25</span></a> Following alpha blockade, when hypovolemia is present and the vascular resistance is decreased, tachycardia develops. This may require beta blockade. Patients may be admitted preoperatively for this medical optimization and fluid management if there are concerns about doing this on an outpatient basis.<a class="citation" href="#romero2015a"><span style="vertical-align: super">26</span></a> Of critical importance to intraoperative safety is pre-surgical optimization, involving endocrinology and/or nephrology and anesthesiology. Postoperatively, patients will need to be monitored for blood pressure control and rebound hypoglycemia, potentially requiring an intensive care unit.</p>

<p>When feasible, minimally invasive surgical techniques are preferable for tumor resection.<a class="citation" href="#dokumcu2018a"><span style="vertical-align: super">27</span></a> However, open resection may be considered for large, locally invasive tumors due to risk of tumor spillage. The approach may be transperitoneal or retroperitoneal depending on surgeon experience.<a class="citation" href="#dokumcu2018a"><span style="vertical-align: super">27,28</span></a> There is very little literature available evaluating safety of the laparoscopic approach in pediatric patients with <abbr title="pheochromocytoma">PCC</abbr>, but the few reports appear to yield favorable results and low intraoperative complications.<a class="citation" href="#fascetti-leon2017a"><span style="vertical-align: super">28</span></a></p>

<p>Cortical sparing surgery (partial adrenalectomy) is recommended for patients with known bilateral disease or patients at high risk of disease recurrence. These would include patients with known hereditary syndromes. To preserve function, about 15% of the adrenal needs to remain.<a class="citation" href="#brauckhoff2008a"><span style="vertical-align: super">29</span></a> However, these patients are at a 10% risk of local recurrence, so need to be followed postoperatively.<a class="citation" href="#yip2004a"><span style="vertical-align: super">30</span></a></p>

<p>Malignant <abbr title="pheochromocytoma">PCC</abbr> is defined by distant spread.<a class="citation" href="#mittal2017a"><span style="vertical-align: super">31</span></a> This is significantly higher in children, up to 50% of cases.<a class="citation" href="#pham2006a"><span style="vertical-align: super">32,33</span></a> Typical sites of metastases are regional lymph nodes, bone, lung and liver. As expected, survival is significantly lower in malignant <abbr title="pheochromocytoma">PCC</abbr> (31% vs. 100% in benign disease).<a class="citation" href="#pham2006a"><span style="vertical-align: super">32</span></a> Despite the high rate of metastases, surgical resection of lesions remains the mainstay of treatment mainly because there are no highly successful alternative therapies. There are therapies to control malignant disease if surgical resection is not possible, but pediatric data are limited. In this scenario, despite extrapolation from the adult literature elsewhere, the inherent differences between tumors in adults and children as well as the impact of toxic therapies in the pediatric population must be considered.</p>

<p>High dose <sup>131</sup>I-<abbr title="metaiodobenzylguanidine">MIBG</abbr> administration can be therapeutic in patients with a positive <abbr title="metaiodobenzylguanidine">MIBG</abbr> and malignant disease.<a class="citation" href="#hulsteijn2014a"><span style="vertical-align: super">34</span></a> The radioactive compound is taken up by the active norepinephrine transporter of <abbr title="pheochromocytoma">PCC</abbr> cells, targeting radiation directly to the cancer cells. In general, tumor volume remains stable with about half of patients having a partial hormone response without progression of disease. However, studies are limited to it is unclear if this is reflective of natural disease progression or a true response to therapy.<a class="citation" href="#hulsteijn2014a"><span style="vertical-align: super">34</span></a> <sup>131</sup>I-<abbr title="metaiodobenzylguanidine">MIBG</abbr> therapy carries a risk of secondary malignancy in children, well documented after neuroblastoma treatment, so this risk must be considered.<a class="citation" href="#garaventa2003a"><span style="vertical-align: super">35</span></a></p>

<p>Radiotherapy can be used, mainly for palliation. External beam radiation therapy has been used alone or with <sup>131</sup>I-<abbr title="metaiodobenzylguanidine">MIBG</abbr> therapy. The goal here is usually maintaining disease stability and less for regression or cure.<a class="citation" href="#fishbein2012a"><span style="vertical-align: super">2</span></a></p>

<p>Multiple chemotherapy regimens have been reported. Generally, these include gemcitabine, docetaxel, vincristine, cyclophosphamide, doxorubicin, and dacarbazine. There are several studies now evaluating guadecitabine, a <abbr title="deoxyribonucleic acid">DNA</abbr> methyl transferase inhibitor, sunitinib, a tyrosine kinase inhibitor, but there are limited data supporting its use.</p>

<h3 id="suggested-follow-up">
<a class="anchor" href="#suggested-follow-up" aria-hidden="true"><span class="octicon octicon-link"></span></a>Suggested Follow Up</h3>

<p>In addition to genetic counseling and germline testing, follow up is recommended at 6 weeks, 6 months and 1 year postoperatively, followed by annual biochemical screening and intermingled abdominal imaging. Follow up involves an inquiry into catecholamine excess symptoms, blood pressure monitoring, and biochemical testing. This follow up is for a lifetime, particularly for recurrent or metastatic disease.<a class="citation" href="#lenders2014a"><span style="vertical-align: super">6</span></a></p>

<h3 id="conclusions">
<a class="anchor" href="#conclusions" aria-hidden="true"><span class="octicon octicon-link"></span></a>Conclusions</h3>

<p>Pediatric <abbr title="pheochromocytoma">PCC</abbr> is rare and most recommendations are extrapolated from adult <abbr title="pheochromocytoma">PCC</abbr>/<abbr title="paraganglioma">PG</abbr> data. Children with <abbr title="pheochromocytoma">PCC</abbr>/<abbr title="paraganglioma">PG</abbr> have a high likelihood of an underlying germline mutation, unlike adults, so genetic counseling should be offered. Diagnosis centers on biochemical testing and cross-sectional imaging, followed by surgical resection. Pre-operative optimization and complete surgical resection are essential.</p>

<h3 class="key-points-head" id="key-points">
<a class="anchor" href="#key-points" aria-hidden="true"><span class="octicon octicon-link"></span></a>Key Points</h3>

<ul class="key-points-list">
  <li>Measure plasma metanephrines and get cross-sectional imaging, ± <abbr title="metaiodobenzylguanidine">MIBG</abbr> or Dotatate <abbr title="positron emission tomography">PET</abbr>
</li>
  <li>Alpha blockade, hydration and NaCl replacement, then beta blockade if necessary pre-operatively</li>
  <li>Resection of lesions is the mainstay of treatment, ideally with minimally invasive methods</li>
  <li>All pediatric patients with <abbr title="pheochromocytoma">PCC</abbr> should be referred for genetic counseling/testing</li>
</ul>

<h2 id="wilms-tumor">
<a class="anchor" href="#wilms-tumor" aria-hidden="true"><span class="octicon octicon-link"></span></a>Wilms’ Tumor</h2>

<h3 id="introduction-1">
<a class="anchor" href="#introduction-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Introduction</h3>

<p>The vast majority of renal masses found in children are Wilms’ tumor (<abbr title="Wilms' tumor">WT</abbr>), but several other rare and important diagnoses can be found. These are summarized in (<a href="#table-3" class="table-link">Table 3</a>)</p>

<p><strong id="table-3" class="table-number">Table 3</strong> Incidence of pediatric renal tumors<a class="citation" href="#d2013a"><span style="vertical-align: super">36</span></a></p>

<table>
  <thead>
    <tr>
      <th>Histology</th>
      <th>Frequency (%)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Favorable Histology Wilms tumor (<abbr title="Wilms' tumor">WT</abbr>)</td>
      <td>75</td>
    </tr>
    <tr>
      <td>Anaplastic <abbr title="Wilms' tumor">WT</abbr>
</td>
      <td>5</td>
    </tr>
    <tr>
      <td>Congenital mesoblastic nephroma (<abbr title="congenital mesoblastic nephroma">CMN</abbr>)</td>
      <td>2</td>
    </tr>
    <tr>
      <td>Clear cell sarcoma of the kidney (<abbr title="clear cell sarcoma of the kidney">CCSK</abbr>)</td>
      <td>3</td>
    </tr>
    <tr>
      <td>Renal Cell Carcinoma (<abbr title="renal cell carcinoma">RCC</abbr>)</td>
      <td>4</td>
    </tr>
    <tr>
      <td>Rhabdoid tumor of the kidney (<abbr title="rhabdoid tumor of the kidney">RTK</abbr>)</td>
      <td>4</td>
    </tr>
    <tr>
      <td>Cystic Nephroma</td>
      <td>2</td>
    </tr>
    <tr>
      <td>Other</td>
      <td>5</td>
    </tr>
  </tbody>
</table>

<p>There exist competing diagnosis and treatment strategies among two international cooperative working groups. The Children’s Oncology Group (<abbr title="Children's Oncology Group">COG</abbr>), responsible for treatment guidelines, tumor registries and clinical trials for renal masses in North America, advocate upfront renal mass excision with the interpretation of primary unaltered pathology and staging guiding further treatment. The Société Internationale d’Oncologie Pédiatrique (<abbr title="Société Internationale d'Oncologie Pédiatrique">SIOP</abbr>), the European equivalent to <abbr title="Children's Oncology Group">COG</abbr>, alternatively advocates for combination vincristine and actinomycin (<abbr title="vincristine and actinomycin">VA</abbr>) neoadjuvant chemotherapy for all patients ≥6 months old with a solid renal mass followed by surgery and then histologic evaluation to guide subsequent therapy.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a> Regardless of approach, survival appears to be similar, but there are nuances and advantages and disadvantages with both approaches. This chapter will focus on the <abbr title="Children's Oncology Group">COG</abbr> guidelines since the authors practice in North America. It is essential to establish early multidisciplinary care with medical oncologists familiar with local ongoing protocols.</p>

<p>In general, it is important to keep a wide differential diagnosis for children with renal masses, as surgical decisions can alter staging, treatment decisions and outcomes. Most renal tumors in children are managed with upfront surgery, usually radical nephrectomy and lymph node (<abbr title="lymph node">LN</abbr>) sampling. Then once pathology is determined, more nuanced decisions for adjuvant treatment are made. An important exception is for bilateral renal tumors, patients with a solitary kidney, history of a known <abbr title="Wilms' tumor">WT</abbr> predisposition syndrome, advanced/locally invasive disease, or inferior vena cava (<abbr title="inferior vena cava">IVC</abbr>) tumor thrombus. These cases are assumed to be <abbr title="Wilms' tumor">WT</abbr> and are managed by upfront chemotherapy followed by attempts at partial nephrectomy to preserve as much renal tissue as possible.</p>

<h3 id="embryology-1">
<a class="anchor" href="#embryology-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Embryology</h3>

<p><abbr title="Wilms' tumor">WT</abbr> develops from dysregulated growth of primitive renal tissue and shows a triphasic pattern of stromal, blastemal and epithelial components. Histology is then further described as favorable or unfavorable (anaplastic), and this guides treatment and prognosis.</p>

<h3 id="epidemiology-1">
<a class="anchor" href="#epidemiology-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Epidemiology</h3>

<p>There are about 500 cases with <abbr title="Wilms' tumor">WT</abbr> in the USA annually.<a class="citation" href="#d2013a"><span style="vertical-align: super">36</span></a> Patients with <abbr title="Wilms' tumor">WT</abbr> are usually 3–5 years old and most cases are diagnosed before age &lt;10y. African-American children seem to be at higher risk of developing <abbr title="Wilms' tumor">WT</abbr>, and patients of Asian decent have the lowest risk of <abbr title="Wilms' tumor">WT</abbr>.</p>

<h3 id="pathogenesis-1">
<a class="anchor" href="#pathogenesis-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Pathogenesis</h3>

<p>While there are several well described syndromes associated with an increased chance of developing <abbr title="Wilms' tumor">WT</abbr>, this is seen in the minority of patients with <abbr title="Wilms' tumor">WT</abbr>. The <em>WT1</em> gene is critically involved with the development of <abbr title="Wilms' tumor">WT</abbr>. This is found on the short arm of chromosome 11 (11p13). <em>WT1</em> is a tumor suppressor gene that codes for a transcription factor that is linked to embryologic genitourinary development. Homozygous mutations of <em>WT1</em>, or nearby coding regions, very often results in the patient developing <abbr title="Wilms' tumor">WT</abbr>.</p>

<p>Multiple genetic syndromes may predispose children to <abbr title="Wilms' tumor">WT</abbr>, as listed in table 1.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a> Patients with predisposition syndromes and bilateral tumors typically present at earlier ages than those without. Screening protocols are often used for these patients to attempt to diagnose tumors at an earlier stage, but whether these impact overall outcomes is unclear. In general, screening protocols involve an abdominal ultrasound every 3–6 months until age 7–10 years.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a></p>

<p><strong id="table-4" class="table-number">Table 4</strong> <abbr title="Wilms' tumor">WT</abbr> Predisposition Syndromes<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a></p>

<table>
  <thead>
    <tr>
      <th>Syndrome</th>
      <th>Genetics</th>
      <th>Associated Features</th>
      <th>Risk of <abbr title="Wilms' tumor">WT</abbr> (%)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><abbr title="Wilms' tumor, aniridia, genital abnormalities, mental delay">WAGR</abbr></td>
      <td>11p13, WT1, PAX13</td>
      <td>
<abbr title="Wilms' tumor">WT</abbr>, Aniridia, Genital abnormalities, Mental delay</td>
      <td>98</td>
    </tr>
    <tr>
      <td>Denys Drash</td>
      <td>WT1</td>
      <td>
<abbr title="Wilms' tumor">WT</abbr>, Genital abnormalities, Renal failure/nephropathy (mesangial sclerosis)</td>
      <td>74</td>
    </tr>
    <tr>
      <td>Beckwith-Weideman</td>
      <td>11p15.5, WT2</td>
      <td>Pre-and post-natal overgrowth, Hemihypertrophy (growth asymmetry), Macroglossia, Anterior abdominal wall defects (omphalocele), Ear creases/pits</td>
      <td>7</td>
    </tr>
    <tr>
      <td>Frasier syndrome</td>
      <td>WT1</td>
      <td>
<abbr title="Wilms' tumor">WT</abbr>, Nephropathy (<abbr title="focal segmental glomerulosclerosis">FSGS</abbr>), Genital abnormalities, Gonadoblastoma/<abbr title="germ cell neoplasia in situ">GCNIS</abbr>
</td>
      <td>6</td>
    </tr>
  </tbody>
</table>

<h3 id="evaluation-and-diagnosis-1">
<a class="anchor" href="#evaluation-and-diagnosis-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Evaluation and Diagnosis</h3>

<p>Patients with any renal mass typical present with a palpable abdominal mass. Hematuria, hypertension, abdominal pain may also be present. It is important to ask about hematuria specifically, as if this is present, the surgeon may consider cystoscopy and retrograde pyelography at the beginning of the case to rule out ureteral tumor extension, which is seen in 2-5% of patients.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a> This may have implications of the level at which the ureter is amputated to avoid intraoperative tumor spillage.</p>

<p>Laboratory studies should include complete blood count, comprehensive metabolic panel and urinalysis. Coagulation studies are critical as an acquired von Willebrand disease is seen in 4–8% of patients with <abbr title="Wilms' tumor">WT</abbr>.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a></p>

<p>The initial imaging modality of choice for a patient with any suspected intra-abdominal mass should be an abdominal ultrasound which then guides further cross-sectional imaging.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a> When a solid renal mass is found, a single <abbr title="computed tomography">CT</abbr> scan of the chest, abdomen and pelvis with iv contrast should be done for staging. For patients with bilateral renal masses, or for patients with another contraindication for <abbr title="computed tomography">CT</abbr> scan, an abdominal and pelvic <abbr title="magnetic resonance imaging">MRI</abbr> with IV contrast is appropriate. Importantly for these patients, <abbr title="computed tomography">CT</abbr> of the chest is still necessary to complete staging.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a> On preoperative imaging, it is important to look for signs of preoperative rupture, enlarged <abbr title="lymph nodes">LNs</abbr>, tumor thrombus in the renal vein or <abbr title="inferior vena cava">IVC</abbr>, and for any renal masses in the contralateral kidney. It is critical to note findings in the contralateral kidney as this changes the approach entirely, to chemotherapy first followed by surgery. Venous tumor thrombus presence will affect surgical planning, and if this extends into the <abbr title="inferior vena cava">IVC</abbr> and especially near the level of the hepatic veins, consideration for chemotherapy prior to surgery is encouraged to avoid cardiac bypass. While imaging findings suspicious for preoperative rupture have low sensitivity (<abbr title="computed tomography">CT</abbr> 76% and <abbr title="magnetic resonance imaging">MRI</abbr> 53%) (Servaes 2014) and are not used for final staging, they can provide guidance as to what the surgeon may encounter in the operating room. Assessment of the involvement of other organs is also important, but keep in mind that <abbr title="Wilms' tumor">WT</abbr> rarely invades surrounding structures, but rather displaces them.</p>

<h3 id="treatment-options-and-their-outcomes-1">
<a class="anchor" href="#treatment-options-and-their-outcomes-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Treatment Options and Their Outcomes</h3>

<p>Pre-operative clinical staging and decisions have significant impact on treatment strategies, as outlined in (<a href="#table-5" class="table-link">Table 5</a>)</p>

<p>The standard of care according to <abbr title="Children's Oncology Group">COG</abbr> surgical protocols for the initial treatment of unilateral, non-syndromic <abbr title="Wilms' tumor">WT</abbr> is open radical nephrectomy with regional <abbr title="lymph node">LN</abbr> sampling. Notably, pre-operative renal mass biopsy is considered spillage of tumor, and results in clinical upstaging to stage III. Biopsy is rarely used in <abbr title="Children's Oncology Group">COG</abbr> protocols due to the intensification of chemotherapy and radiation with upstaging, both of which have significant side effects. Neoadjuvant chemotherapy may be considered in locally advanced, unresectable tumors, and always with bilateral tumors. Those with venous tumor thrombus into the <abbr title="inferior vena cava">IVC</abbr> at or above the hepatic venous confluence or those with overwhelming liver or lung metastases that compromise normal function, based on surgeon and/or anesthesia judgement, may also benefit from neoadjuvant chemotherapy.</p>

<p>In countries were the <abbr title="Société Internationale d'Oncologie Pédiatrique">SIOP</abbr> UMBRELLA protocol is being followed, dual agent Vincristine and Actinomycin-D neoadjuvant chemotherapy for patients older than 6 months of age with localized tumors is the standard of care. The goal of neoadjuvant chemotherapy is to down-stage the tumor as well as aid in the ease of surgical resection. Patients with metastatic disease receive additional Doxorubicin neoadjuvant chemotherapy. Nephrectomy is planned between weeks 5 and 8 depending on tumor stage, and adjuvant chemotherapy is based on the final tumor stage and histology.</p>

<p>Radical nephrectomy, with sparing of the adrenal gland if feasible, should be performed via an open transperitoneal abdominal approach. It is important to palpate the surface of the liver and peritoneal surfaces, biopsying any nodules that are felt. Inspect the peritoneal fluid and if bloody, consider declaring pre-operative rupture vs. sending to pathology for cytology to identify any malignant cells. Carefully document any surrounding structures invasion and palpate the renal vein and <abbr title="inferior vena cava">IVC</abbr> to identify any venous tumor thrombus. Routine exploration of the contralateral kidney is unnecessary with modern use of preoperative cross-sectional imaging. Although <abbr title="lymph node">LN</abbr> sampling is mandated as part of <abbr title="Children's Oncology Group">COG</abbr> surgical protocols, under sampling or omission of <abbr title="lymph node">LN</abbr> sampling is the most common protocol violation. In general, at least 6-10 <abbr title="lymph nodes">LNs</abbr> need to be examined in order to achieve an acceptable false negative rate.<a class="citation" href="#loomis2019a"><span style="vertical-align: super">38</span></a> Additionally, <abbr title="lymph node">LN</abbr> positivity is one of the most common criteria for Stage III disease and has been shown to be an independent predictor of survival when compared to other Stage III variables (Fernandez et al 2018).</p>

<h3 id="special-treatment-scenarios">
<a class="anchor" href="#special-treatment-scenarios" aria-hidden="true"><span class="octicon octicon-link"></span></a>Special Treatment Scenarios</h3>

<p>In general, nephron-sparring surgery (<abbr title="nephron-sparring surgery">NSS</abbr>, partial nephrectomy) is reserved for patients with solitary kidneys, bilateral (stage V) or syndromic tumors and is often preceded by neoadjuvant chemotherapy in an attempt to improve feasibility of <abbr title="nephron-sparring surgery">NSS</abbr>. Importantly, biopsy before chemotherapy when <abbr title="Wilms' tumor">WT</abbr> is the overwhelming likely diagnosis (i.e., age 1–7y), is NOT advocated, as this will result in adjuvant therapy intensification as well. If there is not at least a partial response in tumor size (partial response is ≥30% total tumor size reduction) after 6 weeks of neoadjuvant therapy, consider open renal biopsy to identify either anaplasia or other histology that would change management. <abbr title="lymph node">LN</abbr> sampling on both sides is also important in <abbr title="nephron-sparring surgery">NSS</abbr> for the treatment of bilateral tumors.</p>

<p>Another important group of patients eligible for treatment modification includes children classified as having very low-risk <abbr title="Wilms' tumor">WT</abbr> (<abbr title="very low risk Wilms' tumor">VLRWT</abbr>). To meet the criteria for <abbr title="very low risk Wilms' tumor">VLRWT</abbr>, the patient must be &lt;2y at the time of diagnosis and have a Stage I favorable histology <abbr title="Wilms' tumor">WT</abbr> that weighs &lt;550g. These patients have been shown to have equivalent event free and overall survival (90% and 100% at 4 years) with nephrectomy alone, thus avoiding some of the potential long-term side effects of chemoradiation therapy. Future <abbr title="Children's Oncology Group">COG</abbr> studies will likely expand on the criteria for surgery alone, but these protocols have not been fully developed yet.</p>

<p>Staging is finalized using several factors, described both by the pathologist and the surgeon at the time of surgery. Surgeon findings are emphasized over imaging findings due to poor sensitivity of cross-sectional imaging to estimate things like spillage, lymphadenopathy, surrounding tissue invasion, etc. As with pre-operative renal mass biopsy, intraabdominal tumor implants or pre-operative rupture/intra-operative spill confers clinical stage III disease, all of which are independently associated with poor survival.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a></p>

<p>The most important factor affecting prognosis and treatment is anaplasia, or unfavorable histology.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a> Additionally, loss of heterozygosity (<abbr title="loss of heterozygosity">LOH</abbr>) for both chromosomes 1p and 16q is associated with increased risk of relapse and cancer-specific mortality<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a> and leads to adjuvant chemotherapy intensification. Gain of chromosome 1q has also been shown to be predictive of worse event-free and overall survival and is a more common alteration than the combined <abbr title="loss of heterozygosity">LOH</abbr> abnormalities at 1p and 16q (1q Gain 28% vs combined <abbr title="loss of heterozygosity">LOH</abbr> 11%). Currently, no treatment or staging alterations are based on gain of 1q, but this gene target may be incorporated into future treatment algorithms and study protocols.</p>

<p><strong id="table-5" class="table-number">Table 5</strong> Therapy and clinical outcomes by Wilms’ tumor stage.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a> <abbr title="vincristine and actinomycin">VA</abbr> = vincristine + actinomycin, <abbr title="vincristine + actinomycin + doxorubicin">VAD</abbr> = vincristine + actinomycin + doxorubicin, <abbr title="radiation therapy">XRT</abbr> = external beam radiation, <abbr title="favorable histology">FH</abbr> = favorable histology, <abbr title="unfavorable histology">UH</abbr> = unfavorable histology, ° - Chemotherapeutic agent only, not regimen. Treatment is generally intensified for Combined <abbr title="loss of heterozygosity">LOH</abbr> and not reflected in this table, * = with <abbr title="unfavorable histology">UH</abbr>, use doxorubicin and <abbr title="radiation therapy">XRT</abbr> earlier with lower stages and 5 drug chemotherapy if diffuse <abbr title="unfavorable histology">UH</abbr>, ** = preoperative chemo only indicated with unresectable primary tumor/abdominal disease, *** - exact use of abdominal and chest <abbr title="radiation therapy">XRT</abbr> is dictated by a number of clinical factors and is unique to each patient’s clinical scenario</p>

<table>
  <thead>
    <tr>
      <th>Stage</th>
      <th>Incidence (%)</th>
      <th>Criteria</th>
      <th>Therapy (<abbr title="favorable histology">FH</abbr>)*˚</th>
      <th>4-year survival (%<abbr title="unfavorable histology">UH</abbr>–%<abbr title="favorable histology">FH</abbr>)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>I</td>
      <td>40–45%</td>
      <td>Confined to kidney, negative margin, no nodal involvement</td>
      <td>Radical nephrectomy with <abbr title="lymph node">LN</abbr> sampling** + <abbr title="vincristine and actinomycin">VA</abbr>
</td>
      <td>83–99%</td>
    </tr>
    <tr>
      <td>II</td>
      <td>20%</td>
      <td>Spread beyond kidney, negative margins, no nodal involvement</td>
      <td>Radical  nephrectomy with <abbr title="lymph node">LN</abbr> sampling** + <abbr title="vincristine and actinomycin">VA</abbr>
</td>
      <td>81–98%</td>
    </tr>
    <tr>
      <td>III</td>
      <td>20–25%</td>
      <td>Peritoneal implants, positive margin, preoperative biopsy, preoperative chemotherapy, Intraoperative tumor rupture, nodal involvement</td>
      <td>Radical nephrectomy with <abbr title="lymph node">LN</abbr> sampling** + <abbr title="vincristine + actinomycin + doxorubicin">VAD</abbr> + abdominal <abbr title="radiation therapy">XRT</abbr>
</td>
      <td>72–94%</td>
    </tr>
    <tr>
      <td>IV</td>
      <td>10%</td>
      <td>Metastatic disease</td>
      <td>Radical nephrectomy with <abbr title="lymph node">LN</abbr> sampling** + multi-agent + abdominal and chest*** <abbr title="radiation therapy">XRT</abbr>
</td>
      <td>38–86%</td>
    </tr>
    <tr>
      <td>V</td>
      <td>5%</td>
      <td>Bilateral tumors</td>
      <td>
<abbr title="vincristine + actinomycin + doxorubicin">VAD</abbr> + nephron-sparing surgery with <abbr title="lymph node">LN</abbr> sampling</td>
      <td>55–87%</td>
    </tr>
  </tbody>
</table>

<h3 id="complications">
<a class="anchor" href="#complications" aria-hidden="true"><span class="octicon octicon-link"></span></a>Complications</h3>

<p>Outcomes for <abbr title="Wilms' tumor">WT</abbr> have improved dramatically from the 1900s, owing mainly to improvement in anesthesia techniques and optimization of chemoradiation protocols. Because of the excellent outcomes, <abbr title="Children's Oncology Group">COG</abbr> study now focuses on decreasing long term morbidity from treatment. The important complications seen by patients treated with <abbr title="Wilms' tumor">WT</abbr> are <abbr title="chronic kidney disease">CKD</abbr>, secondary malignancies from both chemotherapy and radiation, cardiac toxicity from doxorubicin and infertility due to chemoradiation exposure.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a></p>

<h3 id="suggested-follow-up-1">
<a class="anchor" href="#suggested-follow-up-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Suggested Follow Up</h3>

<p>Various follow-up recommendations exist for surveillance imaging after treatment for <abbr title="Wilms' tumor">WT</abbr>, with most protocols highlighting the need for more intense surveillance during the first 2 years after treatment. Surveillance imaging options include abdominal ultrasound and chest X-ray screening every 3–6 months for the first 3–4 years followed by yearly imaging after that. Alternatively, cross-sectional imaging with <abbr title="computed tomography">CT</abbr> or <abbr title="magnetic resonance imaging">MRI</abbr> may also be used in surveillance protocols, particularly in high-risk patients or those with indeterminant findings on <abbr title="ultrasound">US</abbr> or X-ray.</p>

<p>Outside of the standard post-operative clinic visits to assess for immediate and long-term surgical complications or disease recurrence, <abbr title="Children's Oncology Group">COG</abbr> has also published long-term follow-up guidelines that cover treatment and organ specific follow-up recommendations aimed at identifying patients at a high risk for long-term complications ranging from non-target organ dysfunction to mental health and infertility issues.</p>

<h3 class="key-points-head" id="key-points-1">
<a class="anchor" href="#key-points-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Key Points</h3>

<ul class="key-points-list">
  <li>Evaluation for a suspected intra-abdominal mass should always begin with ultrasound</li>
  <li>Open surgery is the standard of care for removal of a pediatric renal tumor</li>
  <li>Avoid biopsy unless absolutely necessary and subsequent results will likely alter management</li>
  <li>Always remember to perform <abbr title="lymph node">LN</abbr> sampling at the time of surgery</li>
</ul>

<h3 class="suggested-readings-head" id="suggested-readings">
<a class="anchor" href="#suggested-readings" aria-hidden="true"><span class="octicon octicon-link"></span></a>Suggested Readings</h3>

<ul class="suggested-readings-list">
  <li><span id="saltzman2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Saltzman AF, Cost NG</b></span>. <span style="font-variant: normal">Lesson 19: Childhood Kidney Tumors</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>AUA Update Series</i></span> <span style="text-decoration: none">2018</span>: <span style="text-decoration: none">37</span></span>.</span></span></li>
  <li><span id="saltzman2018b"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Saltzman A, Carrasco A, Weinman J, Meyers M, Cost N</b></span>. <span style="font-variant: normal">Initial imaging for pediatric renal masses: An
  opportunity for improvement</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Urol</i></span> <span style="text-decoration: none">2018; <b>199</b> (5)</span>: <span style="text-decoration: none">1330–1336</span>. <span style="text-decoration: underline">DOI: 10.1016/j.juro.2017.11.076</span></span>.</span></span></li>
  <li><span id="saltzman2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Saltzman A, Smith D, Gao D, Ghosh D, Amini A, Aldrink J, <i>et al.</i></b></span>. <span style="font-variant: normal">How many lymph nodes are enough? Assessing the
  adequacy of lymph node yield for staging in favorable histology
  Wilms’ tumor</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Pediatr Surg</i></span> <span style="text-decoration: none">2019; <b>54</b> (11)</span>: <span style="text-decoration: none">2331–2335</span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpedsurg.2019.06.010</span></span>.</span></span></li>
  <li><span id="cost2022a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Cost NG, Routh JC</b></span>. <i>Wilms Tumor</i>. <span style="text-decoration: underline"><span style="text-decoration: none">AUA University Core Curriculum; 2022</span>, <span style="text-decoration: underline">DOI: 10.1097/01.cot.0000314419.91544.ae</span></span>.</span></span></li>
</ul>

<h3 class="rec-videos-head" id="recommended-videos">
<a class="anchor" href="#recommended-videos" aria-hidden="true"><span class="octicon octicon-link"></span></a>Recommended Videos</h3>

<ul class="rec-videos-list">
  <li><a href="https://www.youtube.com/watch?v=KsRJQv4I9L4">https://www.youtube.com/watch?v=KsRJQv4I9L4</a></li>
</ul>

<h2 id="pediatric-non-wilms-renal-tumors">
<a class="anchor" href="#pediatric-non-wilms-renal-tumors" aria-hidden="true"><span class="octicon octicon-link"></span></a>Pediatric Non-Wilms’ Renal Tumors</h2>

<h3 id="introduction-2">
<a class="anchor" href="#introduction-2" aria-hidden="true"><span class="octicon octicon-link"></span></a>Introduction</h3>

<p>Renal cell carcinoma (<abbr title="renal cell carcinoma">RCC</abbr>) in the pediatric, adolescent and young adult population is an important histologic subtype of renal malignancy with several unique differences in management when compared to the more common <abbr title="Wilms' tumor">WT</abbr> pathology. <abbr title="renal cell carcinoma">RCC</abbr> is similar in appearance to <abbr title="Wilms' tumor">WT</abbr> on standard <abbr title="computed tomography">CT</abbr> or <abbr title="magnetic resonance imaging">MRI</abbr> and should be taken into consideration during the evaluation of a suspected renal malignancy, especially in adolescent children and young adults. Unlike their adult counterparts, pediatric <abbr title="renal cell carcinoma">RCC</abbr> tends to follow a more aggressive clinical course in large part due to differences in the molecular biology of these tumors.</p>

<h3 id="embryology-2">
<a class="anchor" href="#embryology-2" aria-hidden="true"><span class="octicon octicon-link"></span></a>Embryology</h3>

<p>Multiple genetic mutations have been associated with predisposition syndromes for sub-types of <abbr title="renal cell carcinoma">RCC</abbr> (<a href="#table-6" class="table-link">Table 6</a>)</p>

<p><strong id="table-6" class="table-number">Table 6</strong> Genetic syndromes associated with <abbr title="renal cell carcinoma">RCC</abbr>.</p>

<table>
  <thead>
    <tr>
      <th>Genetic  Predisposition Syndrome</th>
      <th>Gene</th>
      <th>Presentation</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Von Hippel Lindau</td>
      <td>
<em><abbr title="Von Hippel Lindau">VHL</abbr></em> (3p)</td>
      <td>Clear cell <abbr title="renal cell carcinoma">RCC</abbr>, Retinal and <abbr title="central nervous system">CNS</abbr> hemangioblastomasm pheochromocytomas, pancreatic cysts/tumors, epididymal cystadenomas</td>
    </tr>
    <tr>
      <td>Tuberous Sclerosis</td>
      <td>
<em>TSC1</em> or <em>TSC2</em>
</td>
      <td>
<abbr title="angiomyolipomas">AMLs</abbr>, clear cell <abbr title="renal cell carcinoma">RCC</abbr>, seizures, mental  retardation, facial angiofibromas, hamartomas</td>
    </tr>
    <tr>
      <td>Hereditary Papillary <abbr title="renal cell carcinoma">RCC</abbr>
</td>
      <td><em>MET</em></td>
      <td>Low grade type 1 papillary <abbr title="renal cell carcinoma">RCC</abbr>
</td>
    </tr>
    <tr>
      <td>Birt-Hogg-Dubé</td>
      <td><em>FLCN</em></td>
      <td>Chromophobe <abbr title="renal cell carcinoma">RCC</abbr>, fibrofolliculomas, lung  cysts and blebs</td>
    </tr>
    <tr>
      <td>Hereditary Leiomyomatosis and <abbr title="renal cell carcinoma">RCC</abbr>
</td>
      <td><em><abbr title="favorable histology">FH</abbr></em></td>
      <td>High grade type 2 papillary <abbr title="renal cell carcinoma">RCC</abbr>, uterine  fibroids at young age, cutaneous leiomyomas</td>
    </tr>
    <tr>
      <td>Succinate  Dehydrogenase <abbr title="renal cell carcinoma">RCC</abbr>
</td>
      <td><em><abbr title="succinate dehydrogenase">SDH</abbr></em></td>
      <td>Different <abbr title="renal cell carcinomas">RCCs</abbr>, paragangliomas, pheochromocytomas</td>
    </tr>
    <tr>
      <td>Sickle hemoglobinopathy</td>
      <td>
<em>Hemoglobin-Beta</em> (11p)</td>
      <td>Renal Medullary Carcinoma</td>
    </tr>
  </tbody>
</table>

<h3 id="epidemiology-2">
<a class="anchor" href="#epidemiology-2" aria-hidden="true"><span class="octicon octicon-link"></span></a>Epidemiology</h3>

<p><abbr title="renal cell carcinoma">RCC</abbr> is the second most common renal tumor in children, accounting for about 4% of cases. The median age at presentation is 12.9 years, and after age 12y, it is the most common pathology found.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37,39</span></a> No significant gender or racial predilection has been described.</p>

<h3 id="pathogenesis-2">
<a class="anchor" href="#pathogenesis-2" aria-hidden="true"><span class="octicon octicon-link"></span></a>Pathogenesis</h3>

<p>Unlike adult tumors where clear cell <abbr title="renal cell carcinoma">RCC</abbr> is the most common <abbr title="renal cell carcinoma">RCC</abbr> subtype (75–88%), the most common histology in children and young adults is translocation <abbr title="renal cell carcinoma">RCC</abbr> (tRCC, 50%). These tumors have activating mutations of <em>TFE3</em> on Xp11.2. This causes continuous tyrosine kinase activity and downstream mTOR pathway activation which results in cellular proliferation. This is a common pathway for <abbr title="renal cell carcinoma">RCC</abbr> development. Despite these tumors often being smaller than their <abbr title="Wilms' tumor">WT</abbr> counterparts, they are aggressive and associated with locally advanced or metastatic disease in 63% of children.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a></p>

<p>This type of tumor is unique in that patients who have received chemotherapeutic drugs during treatment of other malignancies are at higher risk of later developing TFE+<abbr title="renal cell carcinoma">RCC</abbr>. There are several case reports detailing the development of translocation <abbr title="renal cell carcinoma">RCC</abbr> after treatment for neuroblastoma, among others.</p>

<h3 id="evaluation-and-diagnosis-2">
<a class="anchor" href="#evaluation-and-diagnosis-2" aria-hidden="true"><span class="octicon octicon-link"></span></a>Evaluation and Diagnosis</h3>

<p>While most adult tumors are identified incidentally, pediatric <abbr title="renal cell carcinomas">RCCs</abbr> commonly present with symptom, namely a palpable mass or gross hematuria. Laboratory work up is the same as for <abbr title="Wilms' tumor">WT</abbr> (complete blood count, comprehensive metabolic panel and urinalysis). Like for <abbr title="Wilms' tumor">WT</abbr>, abdominal <abbr title="ultrasound">US</abbr> should be the first imaging modality, followed by complete staging with <abbr title="computed tomography">CT</abbr> chest and either <abbr title="computed tomography">CT</abbr> or <abbr title="magnetic resonance imaging">MRI</abbr> with intravenous contrast of the abdomen and pelvis. Staging and grading systems are the same as those used for adult <abbr title="renal cell carcinoma">RCC</abbr> (<a href="#table-7" class="table-link">Table 7</a>)</p>

<p>While <abbr title="nephron-sparring surgery">NSS</abbr> and minimally invasive approaches for adult <abbr title="renal cell carcinoma">RCC</abbr> are considered standard of care, their role in pediatric <abbr title="renal cell carcinoma">RCC</abbr> is less clear. The reason for this is likely multifactorial. This disease is rare, and the pathology is not known preoperatively. <abbr title="Wilms' tumor">WT</abbr> <abbr title="Children's Oncology Group">COG</abbr> surgical protocols emphasize open, radical nephrectomy for the initial treatment of a suspected renal malignancy, which limits the widespread use of laparoscopy and <abbr title="nephron-sparring surgery">NSS</abbr> in general for pediatric <abbr title="renal cell carcinoma">RCC</abbr>, despite the familiarity with urologists with this technique.</p>

<p><strong id="table-7" class="table-number">Table 7</strong> American Joint Committee on Cancer (AJCC) TNM Staging for Renal Cell Carcinoma (7<sup>th</sup> Edition)</p>

<table>
  <thead>
    <tr>
      <th>Stage</th>
      <th>Definitiion</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>T1a</td>
      <td>Tumor confined to kidney, &lt;4 cm</td>
    </tr>
    <tr>
      <td>T1b</td>
      <td>Tumor confined to kidney, ≥4 cm but &lt;7 cm</td>
    </tr>
    <tr>
      <td>T2a</td>
      <td>Tumor  confined to kidney, ≥7 cm but &lt;10  cm</td>
    </tr>
    <tr>
      <td>T2b</td>
      <td>Tumor  confined to kidney, ≥10 cm</td>
    </tr>
    <tr>
      <td>T3a</td>
      <td>Tumor extends grossly into renal vein or its segmental branches, or tumor invades perirenal and/or renal sinus fat but not beyond Gerota’s fascia</td>
    </tr>
    <tr>
      <td>T3b</td>
      <td>Spread to infra-diaphragmatic <abbr title="inferior vena cava">IVC</abbr>
</td>
    </tr>
    <tr>
      <td>T3c</td>
      <td>Spread to supra-diaphragmatic <abbr title="inferior vena cava">IVC</abbr> or <abbr title="inferior vena cava">IVC</abbr> wall invasion</td>
    </tr>
    <tr>
      <td>T4</td>
      <td>Involvement  of ipsilateral adrenal gland or invades beyond Gerota’s fascia</td>
    </tr>
    <tr>
      <td><strong>Nodal Stage</strong></td>
      <td> </td>
    </tr>
    <tr>
      <td>N0</td>
      <td>No nodal involvement</td>
    </tr>
    <tr>
      <td>N1</td>
      <td>Metastatic  involvement of regional <abbr title="lymph node">LN</abbr>
</td>
    </tr>
    <tr>
      <td><strong>Metastasis Stage</strong></td>
      <td> </td>
    </tr>
    <tr>
      <td>M0</td>
      <td>No distant metastases</td>
    </tr>
    <tr>
      <td>M1</td>
      <td>Distant  metastases</td>
    </tr>
    <tr>
      <td><strong>Stage  Groupings</strong></td>
      <td> </td>
    </tr>
    <tr>
      <td>Stage I</td>
      <td>T1 N0 M0</td>
    </tr>
    <tr>
      <td>Stage  II</td>
      <td>T2 N0 M0</td>
    </tr>
    <tr>
      <td>Stage III</td>
      <td>T3 or N1 with M0</td>
    </tr>
    <tr>
      <td>Stage  IV</td>
      <td>T4 or M1</td>
    </tr>
  </tbody>
</table>

<h3 id="treatment-options-and-outcomes">
<a class="anchor" href="#treatment-options-and-outcomes" aria-hidden="true"><span class="octicon octicon-link"></span></a>Treatment Options and Outcomes</h3>

<p>As mentioned previously, surgery is the mainstay of treatment. It is critical that a multi-disciplinary discussion be had between the surgeon and the oncologist to ensure that any possible surgical decisions made (nephron sparing surgery (<abbr title="nephron-sparring surgery">NSS</abbr>) vs. radical nephrectomy (RN), laparoscopy vs. open) or necessitated by the pathology that results from surgery (i.e., positive margin) are considered preoperatively. The downstream consequences of decisions should always be considered up front, as this may change the subsequent treatment, eligibility for research studies, or outcomes.</p>

<p>Surgical treatment revolves around radical nephrectomy versus <abbr title="nephron-sparring surgery">NSS</abbr>, and consideration for laparoscopy should be careful and conservative. <abbr title="lymph node">LN</abbr> sampling is again imperative for translocation <abbr title="renal cell carcinoma">RCC</abbr> in children, and unlike adult <abbr title="renal cell carcinoma">RCC</abbr> where <abbr title="lymph nodes">LNs</abbr> are rarely involved if not clinically suspicious preoperatively, pre-operative staging imaging has low sensitivity (57%) for identifying the high rate (48%) of <abbr title="lymph node">LN</abbr> involvement for cT1 tumors. Extending beyond just children, <abbr title="lymph node">LN</abbr> sampling should be strongly encouraged, for both diagnostic and therapeutic reasons, in patients &lt;40 years of age with a suspicious renal mass.<a class="citation" href="#saltzman2018a"><span style="vertical-align: super">37</span></a> More recent <abbr title="Children's Oncology Group">COG</abbr> data from AREN0321 suggest that complete surgical resection of disease, including all metastatic sites, and therefore presumably any involved <abbr title="lymph nodes">LNs</abbr>, confers a significant survival advantage, highlighting the importance of careful surgical planning and adherence to current protocols.</p>

<p>5-year overall survival is 71–100% for patients with pT1–3 disease, 55% for patients with <abbr title="lymph node">LN</abbr> metastases and just 8% for patients with distant disease. Overall survival trends are lower in children stage-for-stage when compared to adult patients with <abbr title="renal cell carcinoma">RCC</abbr>, a direct correlate to the increased prevalence of tRCC in the younger patient cohort. Traditional adjuvant therapy for adults, such as tyrosine kinase and mammalian target of Rapamycin inhibitors, may be used with advanced disease or adverse pathology, but data are limited in children. The only reported cases of survival in widely metastatic translocation <abbr title="renal cell carcinoma">RCC</abbr> involve complete surgical resection (primary tumor, regional lymph nodes, and metastatic lesions). AREN 1721, a current <abbr title="Children's Oncology Group">COG</abbr> study, is currently examining the benefit of immunotherapy and tyrosine kinase inhibitors in advanced translocation-<abbr title="renal cell carcinoma">RCC</abbr>, which hopefully will add another treatment option for patients with more widespread disease.</p>

<h3 id="complications-1">
<a class="anchor" href="#complications-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Complications</h3>

<p>Complications of treatment for <abbr title="renal cell carcinoma">RCC</abbr> are similar to those for <abbr title="Wilms' tumor">WT</abbr>, namely <abbr title="chronic kidney disease">CKD</abbr> and surgical complications such as bowel obstruction, bleeding, adjacent organ injury, urine leak, etc. Since chemotherapy and radiation are rarely used for this type of tumor, there are not associated side effects from these treatments.</p>

<h3 id="conclusions-1">
<a class="anchor" href="#conclusions-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Conclusions</h3>

<p>Pediatric <abbr title="renal cell carcinoma">RCC</abbr>, although not as common as <abbr title="Wilms' tumor">WT</abbr>, is a very important entity that every pediatric surgeon and urologist should be aware of when treating pediatric, adolescent, and young adult patients with renal tumors. Since these tumors are often indistinguishable from other histologic variants of renal malignancies, <abbr title="renal cell carcinoma">RCC</abbr> should be kept in the differential diagnosis, especially when treating children older than 12 years of age. Because surgery is the mainstay of treatment, careful adherence to surgical protocols with the careful use of <abbr title="nephron-sparring surgery">NSS</abbr> approaches only after thorough multi-disciplinary discussions is vital.</p>

<h3 class="key-points-head" id="key-points-2">
<a class="anchor" href="#key-points-2" aria-hidden="true"><span class="octicon octicon-link"></span></a>Key Points</h3>

<ul class="key-points-list">
  <li>Begin work up with abdominal <abbr title="ultrasound">US</abbr>, single arterial phase <abbr title="computed tomography">CT</abbr> chest, abdomen, pelvis with IV contrast; <abbr title="magnetic resonance imaging">MRI</abbr> of the abdomen and pelvis with IV contrast is an acceptable alternative to abdominopelvic imaging</li>
  <li>Initial treatment is surgical</li>
  <li>Multi-disciplinary discussion of radical nephrectomy vs. <abbr title="nephron-sparring surgery">NSS</abbr> and open vs. laparoscopy is important with the treating oncology team</li>
  <li>Always sample regional <abbr title="lymph nodes">LNs</abbr>, regardless of preoperative imaging appearance as this has low sensitivity</li>
  <li>Small masses often have involved <abbr title="lymph nodes">LNs</abbr>, regardless of preoperative imaging appearance</li>
</ul>

<h3 class="suggested-readings-head" id="suggested-readings-1">
<a class="anchor" href="#suggested-readings-1" aria-hidden="true"><span class="octicon octicon-link"></span></a>Suggested Readings</h3>

<ol class="suggested-readings-list">
  <li><span id="saltzman2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Saltzman AF, Cost NG</b></span>. <span style="font-variant: normal">Lesson 19: Childhood Kidney Tumors</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>AUA Update Series</i></span> <span style="text-decoration: none">2018</span>: <span style="text-decoration: none">37</span></span>.</span></span></li>
  <li><span id="seibel2006a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Seibel NL, Sun J, Anderson B JR, NE P, EJ R, M.L.</b></span>. <span style="font-variant: normal">Outcome of clear cell sarcoma of the kidney (<abbr title="clear cell sarcoma of the kidney">CCSK</abbr>)
 treated on the National Wilms Tumor Study-5 (NWTS</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Oncol</i></span> <span style="text-decoration: none">2006; <b>24</b> (90180)</span>: <span style="text-decoration: none">9000–9000</span>. <span style="text-decoration: underline">DOI: 10.1200/jco.2006.24.18_suppl.9000</span></span>.</span></span></li>
  <li><span id="geller2015a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ</b></span>. <span style="font-variant: normal">Characterization of adolescent and pediatric renal
 cell carcinoma: A report from the Children’s Oncology Group study
 AREN03B2: Adolescent Renal Cell Carcinoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Cancer</i></span> <span style="text-decoration: none">2015; <b>121</b></span>: <span style="text-decoration: none">2457–2464</span>. <span style="text-decoration: underline">DOI: 10.1002/cncr.29368</span></span>.</span></span></li>
  <li><span id="rialon2015a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Rialon KL, Gulack BC, Englum BR, Routh JC, Rice HE</b></span>. <span style="font-variant: normal">Factors impacting survival in children with renal
 cell carcinoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Pediatr Surg</i></span> <span style="text-decoration: none">2015; <b>50</b></span>: <span style="text-decoration: none">1014–1018</span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpedsurg.2015.03.027</span></span>.</span></span></li>
</ol>

<p><strong id="table-supplementary" class="table-number">Supplementary Table</strong> Other Rare Pediatric Renal Tumors</p>

<table>
  <thead>
    <tr>
      <th>Tumor</th>
      <th>Characteristics</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Clear Cell Sarcoma of the Kidney (<abbr title="clear cell sarcoma of the kidney">CCSK</abbr>)</td>
      <td>Age of onset: 1-4yo</td>
    </tr>
    <tr>
      <td> </td>
      <td>M:F= 2:1</td>
    </tr>
    <tr>
      <td> </td>
      <td>Associated with skeletal and brain metastasis</td>
    </tr>
    <tr>
      <td> </td>
      <td>No known familial predisposition syndromes or cases of bilateral <abbr title="clear cell sarcoma of the kidney">CCSK</abbr>.</td>
    </tr>
    <tr>
      <td> </td>
      <td>Radical nephrectomy with <abbr title="lymph node">LN</abbr> sampling</td>
    </tr>
    <tr>
      <td> </td>
      <td>Adjuvant radiation and chemotherapy (vincristine, doxorubicin, cyclophosphamide and etoposide; Seibel 2006)</td>
    </tr>
    <tr>
      <td> </td>
      <td>80-90% 5yr survival</td>
    </tr>
    <tr>
      <td>Rhabdoid Tumor of the Kidney (<abbr title="rhabdoid tumor of the kidney">RTK</abbr>)</td>
      <td>80% &lt;2yo</td>
    </tr>
    <tr>
      <td> </td>
      <td>Germline mutations in INI-1 on chromosome 22</td>
    </tr>
    <tr>
      <td> </td>
      <td>Associated with brain metastasis → <abbr title="magnetic resonance imaging">MRI</abbr> brain during workup; <abbr title="central nervous system">CNS</abbr> involvement almost always fatal</td>
    </tr>
    <tr>
      <td> </td>
      <td>Radical nephrectomy with <abbr title="lymph node">LN</abbr> sampling</td>
    </tr>
    <tr>
      <td> </td>
      <td>Chemotherapy and radioresistant (Denes 2013)</td>
    </tr>
    <tr>
      <td> </td>
      <td>Worst survival of all pediatric renal tumors - 20% 5-year OS</td>
    </tr>
    <tr>
      <td>Congenital Mesoblastic Nephroma (<abbr title="congenital mesoblastic nephroma">CMN</abbr>)</td>
      <td>most common renal tumor in infants &lt;6 months of age</td>
    </tr>
    <tr>
      <td> </td>
      <td>may be seen prenatal ultrasound with polyhydramnios and preterm birth</td>
    </tr>
    <tr>
      <td> </td>
      <td>
<abbr title="computed tomography">CT</abbr> chest, abdomen and pelvis for staging</td>
    </tr>
    <tr>
      <td> </td>
      <td>Radical nephrectomy with <abbr title="lymph node">LN</abbr> sampling is diagnostic and therapeutic</td>
    </tr>
    <tr>
      <td> </td>
      <td>Excellent  prognosis, especially with surgery within the first 6 months of life</td>
    </tr>
    <tr>
      <td> </td>
      <td>Metastasis and recurrence rarely occur, follow with <abbr title="ultrasound">US</abbr> for 2y</td>
    </tr>
    <tr>
      <td>Renal medullary carcinoma (RMC)</td>
      <td>Often in those with sickle cell trait or disease; strong African-American predominance (Denes 2013).</td>
    </tr>
    <tr>
      <td> </td>
      <td>Complete cross-sectional staging imaging is necessary</td>
    </tr>
    <tr>
      <td> </td>
      <td>&gt;90% will have advanced/metastatic disease on presentation</td>
    </tr>
    <tr>
      <td> </td>
      <td>Radical nephrectomy is the primary treatment modality</td>
    </tr>
    <tr>
      <td> </td>
      <td>Unresponsive  to chemoradiation.</td>
    </tr>
    <tr>
      <td> </td>
      <td>OS 4-16 months</td>
    </tr>
    <tr>
      <td>Angiomyolipoma (AML)</td>
      <td>3 histologic components: blood vessels, muscle and adipose</td>
    </tr>
    <tr>
      <td> </td>
      <td>Often present with spontaneous retroperitoneal hemorrhage</td>
    </tr>
    <tr>
      <td> </td>
      <td>Associated with Tuberous Sclerosis Complex</td>
    </tr>
    <tr>
      <td> </td>
      <td>Annual  monitoring with ultrasonography or <abbr title="magnetic resonance imaging">MRI</abbr> for size and stability</td>
    </tr>
    <tr>
      <td> </td>
      <td>
<abbr title="nephron-sparring surgery">NSS</abbr>  if excision needed at all</td>
    </tr>
    <tr>
      <td> </td>
      <td>mTOR inhibitor therapy (everolimus) has been shown to reduce the size and slow progression</td>
    </tr>
    <tr>
      <td> </td>
      <td>Increased risk of <abbr title="renal cell carcinoma">RCC</abbr> and should be considered in fat-poor lesions</td>
    </tr>
    <tr>
      <td>Cystic Tumor Variants: Multilocular Cystic Nephroma (MCN), Cystic Partially differentiated Nephroblastoma (CPDN), Cystic <abbr title="Wilms' tumor">WT</abbr>
</td>
      <td><strong>MCN and CPDN</strong></td>
    </tr>
    <tr>
      <td> </td>
      <td>&lt;2 years of age</td>
    </tr>
    <tr>
      <td> </td>
      <td>MCN associated with DICER-1 mutation (pleuropulmonary blastoma, ovarian stromal tumors)</td>
    </tr>
    <tr>
      <td> </td>
      <td>MCN have benign septae; CPDN have poorly differentiated tissue/blastemal cells in septae</td>
    </tr>
    <tr>
      <td> </td>
      <td>Radical  nephrectomy is curative</td>
    </tr>
    <tr>
      <td> </td>
      <td>If <abbr title="nephron-sparring surgery">NSS</abbr>, use frozen section analysis to confirm negative margin</td>
    </tr>
    <tr>
      <td> </td>
      <td>Stage  II CPDN require vincristine and actinomycin chemotherapy</td>
    </tr>
    <tr>
      <td> </td>
      <td><strong>Cystic  <abbr title="Wilms' tumor">WT</abbr></strong></td>
    </tr>
    <tr>
      <td> </td>
      <td>More  common 3-5yo</td>
    </tr>
    <tr>
      <td> </td>
      <td>More  solid strictures between the cysts with stromal, mesenchymal or epithelial components</td>
    </tr>
    <tr>
      <td> </td>
      <td>Radical nephrectomy with <abbr title="lymph node">LN</abbr> sampling</td>
    </tr>
    <tr>
      <td> </td>
      <td>Adjuvant therapy based on stage-dependent <abbr title="Wilms' tumor">WT</abbr> guidelines</td>
    </tr>
  </tbody>
</table>

<h2 id="references">
<a class="anchor" href="#references" aria-hidden="true"><span class="octicon octicon-link"></span></a>References</h2>

<ol class="bibliography">
<li>
<span id="board2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Board PPTE, editor</b></span>. Unusual Cancers of Childhood Treatment (PDQ(R)):
    Health Professional Version. <span style="text-decoration: underline"><span style="text-decoration: none">In: </span>. <span style="text-decoration: none"><i>PDQ Cancer Information Summaries [Internet]</i></span>. <span style="text-decoration: none">Bethesda (MD: National Cancer Institute; 2019</span></span>.</span></span> </li>
<li>
<span id="bausch2014a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Bausch B, Wellner U, Bausch D</b></span>. <span style="font-variant: normal">Long-term prognosis of patients with pediatric
    pheochromocytoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Endocr Relat Cancer</i></span> <span style="text-decoration: none">2014; <b>21</b> (1)</span>: <span style="text-decoration: none">17–25</span>. <span style="text-decoration: underline">DOI: 10.1530/erc-13-0415</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/24169644" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1530/erc-13-0415" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="bholah2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Bholah R, Bunchman TE</b></span>. <span style="font-variant: normal">Review of Pediatric Pheochromocytoma and
    Paraganglioma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Front Pediatr</i></span> <span style="text-decoration: none">2017; <b>5</b> (155)</span>. <span style="text-decoration: underline">DOI: 10.3389/fped.2017.00155</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/28752085" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.3389/fped.2017.00155" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="lenders2014a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Lenders JW, Duh QY, Eisenhofer G</b></span>. <span style="font-variant: normal">Pheochromocytoma and paraganglioma: an endocrine
    society clinical practice guideline</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Endocrinol Metab</i></span> <span style="text-decoration: none">2014; <b>99</b> (6)</span>: <span style="text-decoration: none">1915–1942</span>. <span style="text-decoration: underline">DOI: 10.1210/jc.2014-1498</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/24893135" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1210/jc.2014-1498" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="chen2010a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Chen H, Sippel RS, O’Dorisio MS</b></span>. <span style="font-variant: normal">The North American Neuroendocrine Tumor Society
    consensus guideline for the diagnosis and management of
    neuroendocrine tumors: pheochromocytoma, paraganglioma, and
    medullary thyroid cancer</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Pancreas</i></span> <span style="text-decoration: none">2010; <b>39</b> (6)</span>: <span style="text-decoration: none">775–783</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/20664475" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a>
</li>
<li>
<span id="pham2006a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Pham TH, Moir C, Thompson GB</b></span>. <span style="font-variant: normal">Pheochromocytoma and paraganglioma in children: a
    review of medical and surgical management at a tertiary care
    center</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Pediatrics</i></span> <span style="text-decoration: none">2006; <b>118</b> (3)</span>: <span style="text-decoration: none">1109–1117</span>. <span style="text-decoration: underline">DOI: 10.1542/peds.2005-2299</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/16951005" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1542/peds.2005-2299" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="king2011a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>King KS, Prodanov T, Kantorovich V</b></span>. <span style="font-variant: normal">Metastatic pheochromocytoma/paraganglioma related to
    primary tumor development in childhood or adolescence: significant
    link to SDHB mutations</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Oncol</i></span> <span style="text-decoration: none">2011; <b>29</b> (31)</span>: <span style="text-decoration: none">4137–4142</span>. <span style="text-decoration: underline">DOI: 10.1200/jco.2011.34.6353</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/21969497" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1200/jco.2011.34.6353" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="neumann2002a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Neumann HP, Bausch B, McWhinney SR</b></span>. <span style="font-variant: normal">Germ-line mutations in nonsyndromic pheochromocytoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>N Engl J Med</i></span> <span style="text-decoration: none">2002; <b>346</b> (19)</span>: <span style="text-decoration: none">1459–1466</span>. <span style="text-decoration: underline">DOI: 10.1056/nejm200209123471117</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/12000816" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1056/nejm200209123471117" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="babic2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Babic B, Patel D, Aufforth R</b></span>. <span style="font-variant: normal">Pediatric patients with pheochromocytoma and
    paraganglioma should have routine preoperative genetic testing for
    common susceptibility genes in addition to imaging to detect
    extra-adrenal and metastatic tumors</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Surgery</i></span> <span style="text-decoration: none">2017; <b>161</b> (1)</span>: <span style="text-decoration: none">220–227</span>. <span style="text-decoration: underline">DOI: 10.1016/j.surg.2016.05.059</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/27865588" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.surg.2016.05.059" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="jha2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Jha A, Luna K, Balili CA</b></span>. <span style="font-variant: normal">Clinical, Diagnostic, and Treatment Characteristics
    of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Front Oncol</i></span> <span style="text-decoration: none">2019; <b>9</b> (53)</span>. <span style="text-decoration: underline">DOI: 10.3389/fonc.2019.00053</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/30854332" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.3389/fonc.2019.00053" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="asai2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Asai S, Katabami T, Tsuiki M, Tanaka Y, Naruse M</b></span>. <span style="font-variant: normal">Controlling Tumor Progression with Cyclophosphamide,
    Vincristine, and Dacarbazine Treatment Improves Survival in
    Patients with Metastatic and Unresectable Malignant
    Pheochromocytomas/Paragangliomas</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Horm Cancer</i></span> <span style="text-decoration: none">2017; <b>8</b> (2)</span>: <span style="text-decoration: none">108–118</span>. <span style="text-decoration: underline">DOI: 10.1007/s12672-017-0284-7</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/28108930" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1007/s12672-017-0284-7" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="fishbein2012a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Fishbein L, Bonner L, Torigian DA</b></span>. <span style="font-variant: normal">External beam radiation therapy (EBRT) for patients
    with malignant pheochromocytoma and non-head and -neck
    paraganglioma: combination with <sup>131</sup>I-MIBG</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Horm Metab Res</i></span> <span style="text-decoration: none">2012; <b>44</b> (5)</span>: <span style="text-decoration: none">405–410</span>. <span style="text-decoration: underline">DOI: 10.1055/s-0032-1308992</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/22566196" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1055/s-0032-1308992" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="boyle2007a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Boyle JG, Davidson DF, Perry CG, Connell JM</b></span>. <span style="font-variant: normal">Comparison of diagnostic accuracy of urinary free
    metanephrines, vanillyl mandelic Acid, and catecholamines and
    plasma catecholamines for diagnosis of pheochromocytoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Endocrinol Metab</i></span> <span style="text-decoration: none">2007; <b>92</b> (12)</span>: <span style="text-decoration: none">4602–4608</span>. <span style="text-decoration: underline">DOI: 10.1210/jc.2005-2668</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/17635948" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1210/jc.2005-2668" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="weise2002a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Weise M, Merke DP, Pacak K, Walther MM, Eisenhofer G</b></span>. <span style="font-variant: normal">Utility of plasma free metanephrines for detecting
    childhood pheochromocytoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Endocrinol Metab</i></span> <span style="text-decoration: none">2002; <b>87</b> (5)</span>: <span style="text-decoration: none">1955–1960</span>. <span style="text-decoration: underline">DOI: 10.1210/jcem.87.5.8446</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/11994324" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1210/jcem.87.5.8446" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="jain2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Jain A, Baracco R, Kapur G</b></span>. <i>Pheochromocytoma and paraganglioma-an update on
    diagnosis, evaluation, and management</i>. <span style="text-decoration: underline"><span style="text-decoration: none">Pediatr Nephrol.; 2019</span>, <span style="text-decoration: underline">DOI: 10.1007/s00467-018-4181-2</span></span>.</span></span>  <a href="https://doi.org/10.1007/s00467-018-4181-2" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="darr2014a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Darr R, Pamporaki C, Peitzsch M</b></span>. <span style="font-variant: normal">Biochemical diagnosis of phaeochromocytoma using
    plasma-free normetanephrine, metanephrine and methoxytyramine:
    importance of supine sampling under fasting conditions</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Clin Endocrinol (Oxf)</i></span> <span style="text-decoration: none">2014; <b>80</b> (4)</span>: <span style="text-decoration: none">478–486</span>. <span style="text-decoration: underline">DOI: 10.1111/cen.12327</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/24102244" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1111/cen.12327" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="boot2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Boot C, Toole B, Johnson SJ, Ball S, Neely D</b></span>. <span style="font-variant: normal">Single-centre study of the diagnostic performance of
    plasma metanephrines with seated sampling for the diagnosis of
    phaeochromocytoma/paraganglioma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Ann Clin Biochem</i></span> <span style="text-decoration: none">2017; <b>54</b> (1)</span>: <span style="text-decoration: none">143–148</span>. <span style="text-decoration: underline">DOI: 10.1177/0004563216650463</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/27170024" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1177/0004563216650463" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="sait2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Sait S, Pandit-Taskar N, Modak S</b></span>. <span style="font-variant: normal">Failure of MIBG scan to detect metastases in
    SDHB-mutated pediatric metastatic pheochromocytoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Pediatr Blood Cancer</i></span> <span style="text-decoration: none">2017; <b>64</b> (11)</span>. <span style="text-decoration: underline">DOI: 10.1002/pbc.26549</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/28409892" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1002/pbc.26549" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="rufini2013a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Rufini V, Treglia G, Castaldi P, Perotti G, Giordano A</b></span>. <span style="font-variant: normal">Comparison of metaiodobenzylguanidine scintigraphy
    with positron emission tomography in the diagnostic work-up of
    pheochromocytoma and paraganglioma: a systematic review</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Q J Nucl Med Mol Imaging</i></span> <span style="text-decoration: none">2013; <b>57</b> (2)</span>: <span style="text-decoration: none">122–133</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/23822989" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a>
</li>
<li>
<span id="b2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>B DP, Silva T N, AT B</b></span>. <span style="font-variant: normal">A Clinical Roadmap to Investigate the Genetic Basis
    of Pediatric Pheochromocytoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Which Genes Should Physicians Think About? Int J
    Endocrinol</i></span> <span style="text-decoration: none">2018; <b>2018</b> (8470642)</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29755524" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a>
</li>
<li>
<span id="makri2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Makri A, Akshintala S, Derse-Anthony C</b></span>. <span style="font-variant: normal">Pheochromocytoma in Children and Adolescents With
    Multiple Endocrine Neoplasia Type 2B</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Endocrinol Metab</i></span> <span style="text-decoration: none">2019; <b>104</b> (1)</span>: <span style="text-decoration: none">7–12</span>. <span style="text-decoration: underline">DOI: 10.1210/jc.2018-00705</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/30113649" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1210/jc.2018-00705" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="igaki2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Igaki J, Nishi A, Sato T, Hasegawa T</b></span>. <span style="font-variant: normal">A pediatric case of pheochromocytoma without
    apparent hypertension associated with von Hippel-Lindau disease</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Clin Pediatr Endocrinol</i></span> <span style="text-decoration: none">2018; <b>27</b> (2)</span>: <span style="text-decoration: none">87–93</span>. <span style="text-decoration: underline">DOI: 10.1297/cpe.27.87</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29662268" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1297/cpe.27.87" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="colvin2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Colvin A, Saltzman AF, Walker J, Bruny J, Cost NG</b></span>. <span style="font-variant: normal">Metastatic Pheochromocytoma in an Asymptomatic
    12-Year-Old With von Hippel-Lindau Disease</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Urology</i></span> <span style="text-decoration: none">2018; <b>119</b></span>: <span style="text-decoration: none">140–142</span>. <span style="text-decoration: underline">DOI: 10.1016/j.urology.2017.12.007</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29545044" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.urology.2017.12.007" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="a2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>A DC, H T, A A, A D, O E, O E</b></span>. <span style="font-variant: normal">Two Childhood Pheochromocytoma Cases due to von
    Hippel-Lindau Disease, One Associated with Pancreatic
    Neuroendocrine Tumor: A Very Rare Manifestation</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Res Pediatr Endocrinol</i></span> <span style="text-decoration: none">2018; <b>10</b> (2)</span>: <span style="text-decoration: none">179–182</span>. <span style="text-decoration: underline">DOI: 10.4274/jcrpe.5078</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29022557" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.4274/jcrpe.5078" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="gruber2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Gruber LM, Erickson D, Babovic-Vuksanovic D, Thompson GB, Young WF Jr., Bancos I</b></span>. <span style="font-variant: normal">Pheochromocytoma and paraganglioma in patients with
    neurofibromatosis type 1</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Clin Endocrinol (Oxf)</i></span> <span style="text-decoration: none">2017; <b>86</b> (1)</span>: <span style="text-decoration: none">141–149</span>. <span style="text-decoration: underline">DOI: 10.1111/cen.13163</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/27460956" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1111/cen.13163" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="tufton2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Tufton N, Sahdev A, Akker SA</b></span>. <span style="font-variant: normal">Radiological Surveillance Screening in Asymptomatic
    Succinate Dehydrogenase Mutation Carriers</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Endocr Soc</i></span> <span style="text-decoration: none">2017; <b>1</b> (7)</span>: <span style="text-decoration: none">897–907</span>. <span style="text-decoration: underline">DOI: 10.1210/js.2017-00230</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29264540" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1210/js.2017-00230" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="settas2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Settas N, Faucz FR, Stratakis CA</b></span>. <span style="font-variant: normal">Succinate dehydrogenase (SDH) deficiency, Carney
    triad and the epigenome</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Mol Cell Endocrinol</i></span> <span style="text-decoration: none">2018; <b>469</b></span>: <span style="text-decoration: none">107–111</span>. <span style="text-decoration: underline">DOI: 10.1016/j.mce.2017.07.018</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/28739378" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.mce.2017.07.018" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="zhao2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Zhao B, Zhou Y, Zhao Y</b></span>. <span style="font-variant: normal">Co-Occurrence of Pheochromocytoma-Paraganglioma and
    Cyanotic Congenital Heart Disease: A</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Case Report and Literature Review Front Endocrinol
    (Lausanne)</i></span> <span style="text-decoration: none">2018; <b>9</b> (165)</span>. <span style="text-decoration: underline">DOI: 10.3389/fendo.2018.00165</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29719528" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.3389/fendo.2018.00165" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="wcislak2019a"></span> </li>
<li>
<span id="song2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Song MK, Kim GB, Bae EJ</b></span>. <span style="font-variant: normal">Pheochromocytoma and paraganglioma in Fontan
    patients: Common more than expected</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Congenit Heart Dis</i></span> <span style="text-decoration: none">2018; <b>13</b> (4)</span>: <span style="text-decoration: none">608–616</span>. <span style="text-decoration: underline">DOI: 10.1111/chd.12625</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/30033572" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1111/chd.12625" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="fishbein2013a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Fishbein L, Orlowski R, Pheochromocytoma/Paraganglioma CD</b></span>. <span style="font-variant: normal">Review of perioperative management of blood pressure
    and update on genetic mutations associated with pheochromocytoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Hypertens (Greenwich)</i></span> <span style="text-decoration: none">2013; <b>15</b> (6)</span>: <span style="text-decoration: none">428–434</span>. <span style="text-decoration: underline">DOI: 10.1111/jch.12084</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/23730992" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1111/jch.12084" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="lebuffe2005a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Lebuffe G, Dosseh ED, Tek G</b></span>. <span style="font-variant: normal">The effect of calcium channel blockers on outcome
    following the surgical treatment of phaeochromocytomas and
    paragangliomas</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Anaesthesia</i></span> <span style="text-decoration: none">2005; <b>60</b> (5)</span>: <span style="text-decoration: none">439–444</span>. <span style="text-decoration: underline">DOI: 10.1111/j.1365-2044.2005.04156.x</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/15819762" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1111/j.1365-2044.2005.04156.x" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="romero2015a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Romero M, Kapur G, Baracco R, Valentini RP, Mattoo TK, Jain A</b></span>. <span style="font-variant: normal">Treatment of Hypertension in Children With
    Catecholamine-Secreting Tumors: A Systematic Approach</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Hypertens (Greenwich)</i></span> <span style="text-decoration: none">2015; <b>17</b> (9)</span>: <span style="text-decoration: none">720–725</span>. <span style="text-decoration: underline">DOI: 10.1111/jch.12571</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/26010736" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1111/jch.12571" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="dokumcu2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Dokumcu Z, Divarci E, Ertan Y, Celik A</b></span>. <span style="font-variant: normal">Laparoscopic adrenalectomy in children: A 25-case
    series and review of the literature</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Journal of Pediatric Surgery</i></span> <span style="text-decoration: none">2018; <b>53</b> (9)</span>: <span style="text-decoration: none">1800–1805</span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpedsurg.2017.11.055</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29254846" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.jpedsurg.2017.11.055" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="fascetti-leon2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Fascetti-Leon F, Scotton G, Pio L</b></span>. <span style="font-variant: normal">Minimally invasive resection of adrenal masses in
    infants and children: results of a European multi-center survey</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Surg Endosc</i></span> <span style="text-decoration: none">2017; <b>31</b> (11)</span>: <span style="text-decoration: none">4505–4512</span>. <span style="text-decoration: underline">DOI: 10.1007/s00464-017-5506-0</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/28550366" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1007/s00464-017-5506-0" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="brauckhoff2008a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Brauckhoff M, Stock K, Stock S</b></span>. <span style="font-variant: normal">Limitations of intraoperative adrenal remnant volume
    measurement in patients undergoing subtotal adrenalectomy</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>World J Surg</i></span> <span style="text-decoration: none">2008; <b>32</b> (5)</span>: <span style="text-decoration: none">863–872</span>. <span style="text-decoration: underline">DOI: 10.1007/s00268-007-9402-y</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/18224482" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1007/s00268-007-9402-y" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="yip2004a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Yip L, Lee JE, Shapiro SE</b></span>. <span style="font-variant: normal">Surgical management of hereditary pheochromocytoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Am Coll Surg</i></span> <span style="text-decoration: none">2004; <b>198</b> (4)</span>: <span style="text-decoration: none">534–525</span>. <span style="text-decoration: underline">DOI: 10.1007/bf02602111</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/15051000" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1007/bf02602111" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="mittal2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Mittal J, Manikandan R, Dorairajan LN, Toi PC</b></span>. <span style="font-variant: normal">Recurrent Malignant Pheochromocytoma with Lymph
    Nodal Metastasis in a Child: A Rare Case</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Indian Assoc Pediatr Surg</i></span> <span style="text-decoration: none">2017; <b>22</b> (4)</span>: <span style="text-decoration: none">242–244</span>. <span style="text-decoration: underline">DOI: 10.4103/0971-9261.214454</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/28974878" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.4103/0971-9261.214454" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="pamporaki2017a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Pamporaki C, Hamplova B, Peitzsch M</b></span>. <span style="font-variant: normal">Characteristics of Pediatric vs Adult
    Pheochromocytomas and Paragangliomas</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Endocrinol Metab</i></span> <span style="text-decoration: none">2017; <b>102</b> (4)</span>: <span style="text-decoration: none">1122–1132</span>. <span style="text-decoration: underline">DOI: 10.1210/jc.2016-3829</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/28324046" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1210/jc.2016-3829" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="kohlenberg2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Kohlenberg J, Welch B, Hamidi O</b></span>. <span style="font-variant: normal">Efficacy and Safety of Ablative Therapy in the
    Treatment of Patients with Metastatic Pheochromocytoma and
    Paraganglioma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Cancers (Basel)</i></span> <span style="text-decoration: none">2019; <b>11</b> (2)</span>. <span style="text-decoration: underline">DOI: 10.3390/cancers11020195</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/30736463" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.3390/cancers11020195" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="paula2016a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>E PM, RI L, GP P</b></span>. <span style="font-variant: normal">Malignant paraganglioma in children treated with
    embolization prior to surgical excision</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>World J Surg Oncol</i></span> <span style="text-decoration: none">2016; <b>14</b> (1)</span>. <span style="text-decoration: underline">DOI: 10.1186/s12957-016-0778-8</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/26837305" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1186/s12957-016-0778-8" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="hulsteijn2014a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>LT H, ND N, OM D, EP C</b></span>. <span style="font-variant: normal">131)I-MIBG therapy for malignant paraganglioma and
    phaeochromocytoma: systematic review and meta-analysis</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Clin Endocrinol (Oxf)</i></span> <span style="text-decoration: none">2014; <b>80</b> (4)</span>: <span style="text-decoration: none">487–501</span>. <span style="text-decoration: underline">DOI: 10.1111/cen.12341</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/24118038" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1111/cen.12341" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="garaventa2003a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Garaventa A, Gambini C, Villavecchia G</b></span>. <span style="font-variant: normal">Second malignancies in children with neuroblastoma
    after combined treatment with
    <sup>131</sup>I-metaiodobenzylguanidine</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Cancer</i></span> <span style="text-decoration: none">2003; <b>97</b> (5)</span>: <span style="text-decoration: none">1332–1338</span>. <span style="text-decoration: underline">DOI: 10.1002/cncr.11167</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/12599242" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1002/cncr.11167" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="ayala-ramirez2012a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Ayala-Ramirez M, Chougnet CN, Habra MA</b></span>. <span style="font-variant: normal">Treatment with sunitinib for patients with
    progressive metastatic pheochromocytomas and sympathetic
    paragangliomas</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Endocrinol Metab</i></span> <span style="text-decoration: none">2012; <b>97</b> (11)</span>: <span style="text-decoration: none">4040–4050</span>. <span style="text-decoration: underline">DOI: 10.1210/jc.2012-2356</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/22965939" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1210/jc.2012-2356" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="saltzman2018a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Saltzman AF, Cost NG</b></span>. <span style="font-variant: normal">Lesson 19: Childhood Kidney Tumors</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>AUA Update Series</i></span> <span style="text-decoration: none">2018</span>: <span style="text-decoration: none">37</span></span>.</span></span> </li>
<li>
<span id="d2013a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Dénes FT, Duarte RJ, Cristófani LM, Lopes RI</b></span>. <span style="font-variant: normal">Pediatric genitourinary oncology</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Front Pediatr</i></span> <span style="text-decoration: none">2013; <b>1</b></span>: <span style="text-decoration: none">48</span>. <span style="text-decoration: underline">DOI: 10.1385/1-59259-421-2:281</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/24400293" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1385/1-59259-421-2:281" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="loomis2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Loomis J, Peard L, Walker J, Cost NG, Saltzman AF</b></span>. <span style="font-variant: normal">Open Radical Nephrectomy for Suspected Renal
    Malignancy–Tips and Tricks</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Urology</i></span> <span style="text-decoration: none">2019</span>. <span style="text-decoration: underline">DOI: 10.1016/j.urology.2019.08.002</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/31419431" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.urology.2019.08.002" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="saltzman2018b"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Saltzman A, Carrasco A, Weinman J, Meyers M, Cost N</b></span>. <span style="font-variant: normal">Initial imaging for pediatric renal masses: An
    opportunity for improvement</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Urol</i></span> <span style="text-decoration: none">2018; <b>199</b> (5)</span>: <span style="text-decoration: none">1330–1336</span>. <span style="text-decoration: underline">DOI: 10.1016/j.juro.2017.11.076</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/29180299" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.juro.2017.11.076" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="saltzman2019a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Saltzman A, Smith D, Gao D, Ghosh D, Amini A, Aldrink J, <i>et al.</i></b></span>. <span style="font-variant: normal">How many lymph nodes are enough? Assessing the
    adequacy of lymph node yield for staging in favorable histology
    Wilms’ tumor</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Pediatr Surg</i></span> <span style="text-decoration: none">2019; <b>54</b> (11)</span>: <span style="text-decoration: none">2331–2335</span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpedsurg.2019.06.010</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/31255328" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.jpedsurg.2019.06.010" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="cost2022a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Cost NG, Routh JC</b></span>. <i>Wilms Tumor</i>. <span style="text-decoration: underline"><span style="text-decoration: none">AUA University Core Curriculum; 2022</span>, <span style="text-decoration: underline">DOI: 10.1097/01.cot.0000314419.91544.ae</span></span>.</span></span> <a href="https://university.auanet.org/core/pediatric/genitourinary-pediatric-oncology/index.cfm" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1097/01.cot.0000314419.91544.ae" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="seibel2006a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Seibel NL, Sun J, Anderson B JR, NE P, EJ R, M.L.</b></span>. <span style="font-variant: normal">Outcome of clear cell sarcoma of the kidney (CCSK)
    treated on the National Wilms Tumor Study-5 (NWTS</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Clin Oncol</i></span> <span style="text-decoration: none">2006; <b>24</b> (90180)</span>: <span style="text-decoration: none">9000–9000</span>. <span style="text-decoration: underline">DOI: 10.1200/jco.2006.24.18_suppl.9000</span></span>.</span></span>  <a href="https://doi.org/10.1200/jco.2006.24.18_suppl.9000" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="geller2015a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ</b></span>. <span style="font-variant: normal">Characterization of adolescent and pediatric renal
    cell carcinoma: A report from the Children’s Oncology Group study
    AREN03B2: Adolescent Renal Cell Carcinoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>Cancer</i></span> <span style="text-decoration: none">2015; <b>121</b></span>: <span style="text-decoration: none">2457–2464</span>. <span style="text-decoration: underline">DOI: 10.1002/cncr.29368</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/25845370" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1002/cncr.29368" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
<li>
<span id="rialon2015a"><span style="font-weight: normal; text-decoration: none"><span style="font-weight: normal"><b>Rialon KL, Gulack BC, Englum BR, Routh JC, Rice HE</b></span>. <span style="font-variant: normal">Factors impacting survival in children with renal
    cell carcinoma</span>. <span style="text-decoration: underline"><span style="text-decoration: none"><i>J Pediatr Surg</i></span> <span style="text-decoration: none">2015; <b>50</b></span>: <span style="text-decoration: none">1014–1018</span>. <span style="text-decoration: underline">DOI: 10.1016/j.jpedsurg.2015.03.027</span></span>.</span></span> <a href="https://pubmed.ncbi.nlm.nih.gov/25805005" title="" data-link="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a sitio web externo"><i class="fa-regular fa-up-right-from-square"></i></a> <a href="https://doi.org/10.1016/j.jpedsurg.2015.03.027" title="" data-doi="1" data-toggle="tooltip" data-placement="top" data-original-title="Enlace a DOI"><i class="ai2 ai-doi"></i></a>
</li>
</ol>


            
            <!--Last repository commit: 6cdbeb2-->
            <p class="last-modified"><i class="fas fa-clock pr-2"></i><em>Última actualización: 2023-01-29 15:12</em></p>
          </div> <!-- /col -->
        </div> <!-- /row -->
      </div> <!-- /container -->
    </div> <!-- /main -->
    
    <footer id="footer">
      <div class="container">
        <div class="row py-5">
          <div class="col-md-4 d-flex justify-content-center justify-content-md-start mb-4 mb-lg-0">
            <a href="https://beta.pediatricurologybook.com/es/" class="logo pr-0 pr-lg-3 pl-3 pl-md-0">
                <img alt="Pediatric Urology Book" class="img-responsive" src="https://beta.pediatricurologybook.com/assets/site-img/pediatricurologybook-white.svg">
            </a>
          </div>
        </div>
      </div>
      <div class="footer-copyright footer-copyright-style-2">
        <div class="container py-2">
          <div class="row py-4">
            <div class="col-lg-4 d-flex align-items-end justify-content-center justify-content-md-start mb-2 mb-lg-0">
              <p>© 2023 por <a href="https://beta.pediatricurologybook.com/es/">Pediatric Urology Book</a>. Todos los derechos reservados.</p>
            </div>
            <div class="col-lg-8 d-flex flex-column mb-4 mb-lg-0">
              <div class="row">
                <div class="col-12 d-flex align-items-center justify-content-center justify-content-md-end m-0 p-0"><ul class="footer-social-icons social-icons social-icons-clean social-icons-icon-light"><li class="social-icons-github"><a href="https://www.github.com/kylerove/pediatricurologybook" target="_blank" title="GitHub"><i class="fab fa-github-alt"></i></a></li><li class="social-icons-twitter"><a href="https://www.twitter.com/PedUrologyBook" target="_blank" title="Twitter"><i class="fab fa-twitter"></i></a></li><li class="social-icons-mastodon"><a rel="me" href="https://med-mastodon.com/@" target="_blank" title="Mastodon"><i class="fab fa-mastodon"></i></a></li><li class="social-icons-youtube"><a href="https://www.youtube.com/@pediatricurologybook" target="_blank" title="Youtube"><i class="fab fa-youtube"></i></a></li></ul></div>
              </div>
              <div class="row">
                <div class="col-12 d-flex align-items-center justify-content-center justify-content-md-end m-0 p-0">
                  <nav id="sub-menu">
                    <ul>
                      <li><i class="fas fa-map-marker"></i> <a href="https://beta.pediatricurologybook.com/es/site-map/">Mapa del Sitio</a></li><li><i class="fas fa-envelope"></i><a href="mailto:editors%40pediatricurologybook.com" class="opacity-7 pl-1">editors@pediatricurologybook.com</a></li></ul>
                  </nav>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </footer>
</div>
    
    <!-- Search -->
    <script src="https://beta.pediatricurologybook.com/assets/js/search.min.js"></script>
    
    <!-- Vendor -->
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery/jquery.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery.appear/jquery.appear.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery.easing/jquery.easing.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery.validation/jquery.validate.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/jquery.stupidtable/stupidtable.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/popper/umd/popper.min.js"></script>
    <script src="https://beta.pediatricurologybook.com/assets/vendor/bootstrap/js/bootstrap.min.js"></script>
    
    <!-- Theme Base, Components and Settings -->
    <script src="https://beta.pediatricurologybook.com/assets/js/theme.js"></script>
    
    <!-- Current Page --><script src="https://beta.pediatricurologybook.com/assets/js/pages/chapter.js"></script>
    
    
    <!-- Theme Custom -->
    <script src="https://beta.pediatricurologybook.com/assets/js/custom.js"></script>
    
    <!-- Theme Initialization Files -->
    <script src="https://beta.pediatricurologybook.com/assets/js/theme.init.js"></script>
    
    <!-- Scroll to top -->
    <a class="scroll-to-top hidden-mobile" href="#"><i class="fas fa-chevron-up"></i></a>
    
  </body>
</html>
